<!DOCTYPE html><html><head><title>Help for package replicateBE</title>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
<link href="https://cdnjs.cloudflare.com/ajax/libs/prism/1.29.0/themes/prism.min.css" rel="stylesheet" />
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/katex@0.15.3/dist/katex.min.css">
<script type="text/javascript">
const macros = { "\\R": "\\textsf{R}", "\\code": "\\texttt"};
function processMathHTML() {
    var l = document.getElementsByClassName('reqn');
    for (let e of l) { katex.render(e.textContent, e, { throwOnError: false, macros }); }
    return;
}</script>
<script defer src="https://cdn.jsdelivr.net/npm/katex@0.15.3/dist/katex.min.js"
    onload="processMathHTML();"></script>
<link rel="stylesheet" type="text/css" href="R-nav.css" />
</head><body><div class="container"><nav class="package" aria-label="Topic Navigation">
<div class="dropdown-menu">
<h1>Package {replicateBE}</h1>
<h2>Contents</h2>
<ul class="menu">
<li><a href='#ABE'>
<p>Comparative BA-calculation for Average Bioequivalence</p></a></li>
<li><a href='#method.A'>
<p>Comparative BA-calculation for Average Bioequivalence with Expanding Limits by the EMA's 'Method A'</p></a></li>
<li><a href='#method.B'>
<p>Comparative BA-calculation for Average Bioequivalence with Expanding Limits by the EMA's 'Method B'</p></a></li>
<li><a href='#refdata'>
<p>Reference Datasets</p></a></li>
<li><a href='#TR.RT.TT.RR'>
<p>Reference Dataset for TR|RT|TT|RR Replicate Designs</p></a></li>
<li><a href='#TRR.RTR'>
<p>Reference Dataset for TRR|RTR (extra-reference) Designs</p></a></li>
<li><a href='#TRR.RTR.RRT'>
<p>Reference Datasets for TRR|RTR|RRT (partial) Replicate Designs</p></a></li>
<li><a href='#TRR.RTT'>
<p>Reference Dataset for TRR|RTT Replicate Designs</p></a></li>
<li><a href='#TRRT.RTTR'>
<p>Reference Datasets for TRRT|RTTR Replicate Designs</p></a></li>
<li><a href='#TRRT.RTTR.TTRR.RRTT'>
<p>Reference Dataset for TRRT|RTTR|TTRR|RRTT Designs</p></a></li>
<li><a href='#TRT.RTR'>
<p>Reference Datasets for TRT|RTR Replicate Designs</p></a></li>
<li><a href='#TRTR.RTRT'>
<p>Reference Datasets for TRTR|RTRT Designs</p></a></li>
<li><a href='#TRTR.RTRT.TRRT.RTTR'>
<p>Reference Dataset for TRTR|RTRT|TRRT|RTTR Designs</p></a></li>
<li><a href='#TTRR.RRTT'>
<p>Reference Datasets for TTRR|RRTT Designs</p></a></li>
</ul>
</div>
<hr>
</nav>
<main>
<table>
<tr>
<td>Encoding:</td>
<td>UTF-8</td>
</tr>
<tr>
<td>Version:</td>
<td>1.1.3</td>
</tr>
<tr>
<td>Date:</td>
<td>2022-05-02</td>
</tr>
<tr>
<td>Title:</td>
<td>Average Bioequivalence with Expanding Limits (ABEL)</td>
</tr>
<tr>
<td>Author:</td>
<td>Helmut Schütz <a href="https://orcid.org/0000-0002-1167-7880"><img alt="ORCID iD"src="https://cloud.R-project.org/web/orcid.svg" style="width:16px; height:16px; margin-left:4px; margin-right:4px; vertical-align:middle" /></a>
    [aut, cre],
  Michael Tomashevskiy [ctb],
  Detlew Labes <a href="https://orcid.org/0000-0003-2169-426X"><img alt="ORCID iD"src="https://cloud.R-project.org/web/orcid.svg" style="width:16px; height:16px; margin-left:4px; margin-right:4px; vertical-align:middle" /></a>
    [ctb]</td>
</tr>
<tr>
<td>Maintainer:</td>
<td>Helmut Schütz &lt;helmut.schuetz@bebac.at&gt;</td>
</tr>
<tr>
<td>Depends:</td>
<td>R (&ge; 3.5.0)</td>
</tr>
<tr>
<td>Imports:</td>
<td>readxl (&ge; 1.0.0), PowerTOST (&ge; 1.5.3), lmerTest, nlme,
pbkrtest, graphics, grDevices</td>
</tr>
<tr>
<td>Suggests:</td>
<td>knitr, rmarkdown, testthat, devtools</td>
</tr>
<tr>
<td>Description:</td>
<td>Performs comparative bioavailability calculations for Average
    Bioequivalence with Expanding Limits (ABEL). Implemented are 'Method A' /
    'Method B' and the detection of outliers. If the design allows, assessment
    of the empiric Type I Error and iteratively adjusting alpha to control the
    consumer risk. Average Bioequivalence - optionally with a tighter (narrow
    therapeutic index drugs) or wider acceptance range (South Africa: Cmax) -
    is implemented as well.</td>
</tr>
<tr>
<td>License:</td>
<td><a href="https://www.r-project.org/Licenses/GPL-3">GPL (&ge; 3)</a></td>
</tr>
<tr>
<td>LazyData:</td>
<td>true</td>
</tr>
<tr>
<td>VignetteBuilder:</td>
<td>knitr</td>
</tr>
<tr>
<td>URL:</td>
<td><a href="https://github.com/Helmut01/replicateBE">https://github.com/Helmut01/replicateBE</a></td>
</tr>
<tr>
<td>BugReports:</td>
<td><a href="https://github.com/Helmut01/replicateBE/issues">https://github.com/Helmut01/replicateBE/issues</a></td>
</tr>
<tr>
<td>NeedsCompilation:</td>
<td>no</td>
</tr>
<tr>
<td>Packaged:</td>
<td>2022-05-02 19:06:36 UTC; HS</td>
</tr>
<tr>
<td>Repository:</td>
<td>CRAN</td>
</tr>
<tr>
<td>Date/Publication:</td>
<td>2022-05-02 22:52:03 UTC</td>
</tr>
</table>
<hr>
<h2 id='ABE'>
Comparative BA-calculation for Average Bioequivalence
</h2><span id='topic+ABE'></span>

<h3>Description</h3>

<p>This function performs the required calculations for the <abbr><span class="acronym">BE</span></abbr>
decision via conventional (unscaled) Average Bioequivalence based on
<abbr><span class="acronym">ANOVA</span></abbr> as recommended in the <abbr><span class="acronym">EMA</span></abbr>’s guideline.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>ABE(alpha = 0.05, path.in, path.out = tempdir(), file, set = "",
    ext, na = ".", sep = ",", dec = ".", logtrans = TRUE,
    print = TRUE, details = FALSE, verbose = FALSE, ask = FALSE,
    data = NULL, theta1, theta2)
</code></pre>


<h3>Arguments</h3>

<table>
<tr><td><code id="ABE_+3A_alpha">alpha</code></td>
<td>

<p>Type I Error (<abbr><span class="acronym">TIE</span></abbr>) probability (nominal level of the test).
Conventionally set to 0.05, resulting in a
100(1&nbsp;&ndash;&nbsp;2<em>&alpha;</em>)
confidence interval.
</p>
</td></tr>
<tr><td><code id="ABE_+3A_path.in">path.in</code></td>
<td>

<p>Path to the data file for import.
</p>
</td></tr>
<tr><td><code id="ABE_+3A_path.out">path.out</code></td>
<td>

<p>Path to save the result file if <code>print = TRUE</code>. You must have
write-permission to the folder. For simplicity your home folder <code style="white-space: pre;">&#8288;"~/"&#8288;</code> can be used.<br />
If missing, R’s standard temporary folder will be used.
</p>
</td></tr>
<tr><td><code id="ABE_+3A_file">file</code></td>
<td>

<p>Name of the dataset for import (<em>without</em> extension). Must be a string
(<em>i.e.</em>, enclosed in single or double quotation marks). The name is
case-sensitive.
</p>
</td></tr>
<tr><td><code id="ABE_+3A_set">set</code></td>
<td>

<p>Name of the sheet of an Excel-file (mandatory). Must be a string (<em>i.e.</em>,
enclosed in single or double quotation marks). The name is case-sensitive.
</p>
</td></tr>
<tr><td><code id="ABE_+3A_ext">ext</code></td>
<td>

<p>File-extension enclosed in single or double quotation marks.
Acceptable are <code style="white-space: pre;">&#8288;"csv"&#8288;</code> for character delimited
variables (<abbr><span class="acronym">CSV</span></abbr>) or <code style="white-space: pre;">&#8288;"xls"&#8288;</code>, <code style="white-space: pre;">&#8288;"xlsx"&#8288;</code> for Excel-files.<br />
The file-extension is not case-sensitive.
</p>
</td></tr>
<tr><td><code id="ABE_+3A_na">na</code></td>
<td>

<p>Character string denoting missing values. Acceptable are <code style="white-space: pre;">&#8288;"NA"&#8288;</code>
(not available), <code style="white-space: pre;">&#8288;"ND"&#8288;</code> (not determined), <code style="white-space: pre;">&#8288;"."&#8288;</code> (<abbr><span class="acronym">SAS</span></abbr>),
<code style="white-space: pre;">&#8288;"Missing"&#8288;</code> (Phoenix WinNonlin), and <code style="white-space: pre;">&#8288;""&#8288;</code> (<abbr><span class="acronym">Excel</span></abbr>;
empty cell). Missings will be converted to <code style="white-space: pre;">&#8288;NA&#8288;</code> in the imported
data. Defaults to <code style="white-space: pre;">&#8288;"."&#8288;</code>.
</p>
</td></tr>
<tr><td><code id="ABE_+3A_sep">sep</code></td>
<td>

<p>Variable separator in the <abbr><span class="acronym">CSV</span></abbr>-file. Acceptable are <code style="white-space: pre;">&#8288;","&#8288;</code>
(comma = <code style="white-space: pre;">&#8288;ASCII 44&#8288;</code>), <code style="white-space: pre;">&#8288;";"&#8288;</code> (semicolon = <code style="white-space: pre;">&#8288;ASCII 59&#8288;</code>),
and <code style="white-space: pre;">&#8288;"\t"&#8288;</code> (tabulator = <code style="white-space: pre;">&#8288;ASCII 9&#8288;</code>). Defaults to <code style="white-space: pre;">&#8288;","&#8288;</code>.
</p>
</td></tr>
<tr><td><code id="ABE_+3A_dec">dec</code></td>
<td>

<p>Decimal separator in the <abbr><span class="acronym">CSV</span></abbr>-file. Acceptable are <code style="white-space: pre;">&#8288;"."&#8288;</code>
(period = <code style="white-space: pre;">&#8288;ASCII 46&#8288;</code>) or <code style="white-space: pre;">&#8288;","&#8288;</code> (comma = <code style="white-space: pre;">&#8288;ASCII 44&#8288;</code>).
Defaults to <code style="white-space: pre;">&#8288;"."&#8288;</code>.
</p>
</td></tr>
<tr><td><code id="ABE_+3A_logtrans">logtrans</code></td>
<td>

<p>If <code>TRUE</code> (default) the raw data (provided in column <code style="white-space: pre;">&#8288;PK&#8288;</code>)
will be internally log-transformed and used in the calculations.
If <code>FALSE</code> the already log-transformed data (provided in the
column <code style="white-space: pre;">&#8288;logPK&#8288;</code>) will be used in the calculations.
</p>
</td></tr>
<tr><td><code id="ABE_+3A_print">print</code></td>
<td>

<p>If <code>TRUE</code> (default), the function prints its results to a
file. If <code>FALSE</code>, returns a data frame of results.
</p>
</td></tr>
<tr><td><code id="ABE_+3A_details">details</code></td>
<td>

<p>Defaults to <code>FALSE</code>. If <code>TRUE</code>, the function sends
its results in 7-digits precision to a data frame.
</p>
</td></tr>
<tr><td><code id="ABE_+3A_verbose">verbose</code></td>
<td>

<p>Defaults to <code>FALSE</code>. If <code>TRUE</code> the ANOVA-table is send to
the console.
</p>
</td></tr>
<tr><td><code id="ABE_+3A_ask">ask</code></td>
<td>

<p>Defaults to <code>FALSE</code>. If <code>TRUE</code> the user will be asked
whether an already existing result file should be overwritten.
</p>
</td></tr>
<tr><td><code id="ABE_+3A_data">data</code></td>
<td>

<p>Specification of one of the internal reference datasets (<code style="white-space: pre;">&#8288;rds01&#8288;</code> to <code style="white-space: pre;">&#8288;rds30&#8288;</code>). If given, the arguments <code style="white-space: pre;">&#8288;path.in&#8288;</code>, <code style="white-space: pre;">&#8288;file&#8288;</code>, <code style="white-space: pre;">&#8288;set&#8288;</code>,
and <code style="white-space: pre;">&#8288;ext&#8288;</code> are ignored. For its use see the examples.<br />
If not given, defaults to <code>NULL</code> (<em>i.e.</em>, import data
from a file).
</p>
</td></tr>
<tr><td><code id="ABE_+3A_theta1">theta1</code></td>
<td>

<p>Lower limit of the acceptance range. Defaults to <code style="white-space: pre;">&#8288;0.80&#8288;</code>. If missing
will be set to <code>1/theta2</code>.
</p>
</td></tr>
<tr><td><code id="ABE_+3A_theta2">theta2</code></td>
<td>

<p>Upper limit of the acceptance range. Defaults to <code style="white-space: pre;">&#8288;1.25&#8288;</code>. If missing
will be set to <code>1/theta1</code>.
</p>
</td></tr>
</table>


<h3>Details</h3>

<p>The model for the treatment comparison is<br />
<code>lm(log(PK) ~ sequence + subject%in%sequence + period + treatment, data = data)</code><br />
where all effects are fixed.<br /><br />
Tested designs
</p>

<ul>
<li><p> 4-period 2-sequence full replicates<br />
<code style="white-space: pre;">&#8288;TRTR | RTRT&#8288;</code><br />
<code style="white-space: pre;">&#8288;TRRT | RTTR&#8288;</code><br />
<code style="white-space: pre;">&#8288;TTRR | RRTT&#8288;</code>
</p>
</li>
<li><p> 2-period 4-sequence replicate<br />
<code style="white-space: pre;">&#8288;TR | RT | TT | RR &#8288;</code> (Balaam’s design)
</p>
</li>
<li><p> 4-period 4-sequence full replicates<br />
<code style="white-space: pre;">&#8288;TRTR | RTRT | TRRT | RTTR&#8288;</code><br />
<code style="white-space: pre;">&#8288;TRRT | RTTR | TTRR | RRTT&#8288;</code>
</p>
</li>
<li><p> 3-period 2-sequence full replicates<br />
<code style="white-space: pre;">&#8288;TRT | RTR&#8288;</code><br />
<code style="white-space: pre;">&#8288;TRR | RTT&#8288;</code>
</p>
</li>
<li><p> 3-period (partial) replicates<br />
<code style="white-space: pre;">&#8288;TRR | RTR | RRT&#8288;</code><br />
<code style="white-space: pre;">&#8288;TRR | RTR &#8288;</code> (extra-reference design)
</p>
</li></ul>

<p>Data structure
</p>

<ul>
<li><p> Columns must have the headers <code>subject</code>, <code>period</code>,
<code>sequence</code>, <code>treatment</code>, <code>PK</code>, and/or <code>logPK</code>.<br />
Any order of columns is acceptable.<br />
Uppercase and mixed case headers will be internally converted to lowercase headers.
</p>

<ul>
<li> <p><code>subject</code> must be integer numbers or (any combination of) alphanumerics<br />
<code style="white-space: pre;">&#8288;[A-Z, a-z, -, _, #, 0-9]&#8288;</code>
</p>
</li>
<li> <p><code>period</code> must be integer numbers.
</p>
</li>
<li> <p><code>sequence</code> must be contained in the tested designs (numbers or
<em>e.g.</em>, <code style="white-space: pre;">&#8288;ABAB&#8288;</code> are not acceptable).
</p>
</li>
<li><p> The Test treatment must be coded <code>T</code> and the Reference <code>R</code>.
</p>
</li></ul>

</li></ul>



<h3>Value</h3>

<p>Prints results to a file if argument <code>print = TRUE</code> (default).<br />
If argument <code>print = FALSE</code>, returns a data frame with the elements:
</p>

<table>
<tr>
 <td style="text-align: left;">
    <code>Design</code> </td><td style="text-align: left;"> <em>e.g.</em>, TRTR|RTRT</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>Method</code> </td><td style="text-align: left;"> ABE</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>n</code> </td><td style="text-align: left;"> total number of subjects</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>nTT</code> </td><td style="text-align: left;"> number of subjects with two treatments of <code>T</code> (full replicates only)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>nRR</code> </td><td style="text-align: left;"> number of subjects with two treatments of <code>R</code></td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>Sub/seq</code> </td><td style="text-align: left;"> number of subjects per sequence</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>Miss/seq</code> </td><td style="text-align: left;"> if the design is unbalanced, number of missings per sequence</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>Miss/per</code> </td><td style="text-align: left;"> if the design is incomplete, number of missings per period</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>alpha</code> </td><td style="text-align: left;"> nominal level of the test</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>DF</code> </td><td style="text-align: left;"> degrees of freedom of the treatment comparison</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>CVwT(%)</code> </td><td style="text-align: left;"> intra-subject coefficient of variation of the test treatment (full replicates only)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>CVwR(%)</code> </td><td style="text-align: left;"> intra-subject coefficient of variation of the reference treatment</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>BE.lo(%)</code> </td><td style="text-align: left;"> lower bioequivalence limit (<em>e.g.</em>, <code style="white-space: pre;">&#8288; 80&#8288;</code>)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>BE.hi(%)</code> </td><td style="text-align: left;"> upper bioequivalence limit (<em>e.g.</em>, <code style="white-space: pre;">&#8288;125&#8288;</code>)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>CI.lo(%)</code> </td><td style="text-align: left;"> lower confidence limit of the treatment comparison</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>CI.hi(%)</code> </td><td style="text-align: left;"> upper confidence limit of the treatment comparison</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>PE(%)</code> </td><td style="text-align: left;"> point estimate of the treatment comparison (aka <abbr><span class="acronym">GMR</span></abbr>)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>BE</code> </td><td style="text-align: left;"> assessment whether the 100(1&nbsp;&ndash;&nbsp;2<em>&alpha;</em>) <abbr><span class="acronym">CI</span></abbr> lies entirely within the acceptance range (<code style="white-space: pre;">&#8288;pass|fail&#8288;</code>)
  </td>
</tr>

</table>



<h3>Warning</h3>

<p>Files may contain a commentary header. If reading from a <abbr><span class="acronym">CSV</span></abbr>-file,
<em>each</em> line of the commentary header <em>must</em> start with <code style="white-space: pre;">&#8288;"# "&#8288;</code>
(hashmark space = <code style="white-space: pre;">&#8288;ASCII 35 ASCII 32&#8288;</code>). If reading from an Excel-file
all lines preceding the column headers are treated as a comment.
</p>


<h3>Clarification</h3>

<p>The &lsquo;ASCII line chart&rsquo; in the result file gives the confidence
limits with filled black squares and the point estimate as a white rhombus.
If a confidence limit exceeds the drawing range, it is shown as a triangle.
The <abbr><span class="acronym">BE</span></abbr> limits and 100% are given with single vertical lines. The
&lsquo;resolution&rsquo; is approximatelly 0.5% and therefore, not all symbols
might be shown. The <abbr><span class="acronym">CI</span></abbr> and <abbr><span class="acronym">PE</span></abbr> take presedence over the limits.
</p>


<h3>Disclaimer</h3>

<p><em>Program offered for Use without any Guarantees and Absolutely No Warranty. No Liability is accepted for any Loss and Risk to Public Health Resulting from Use of this R-Code.</em>
</p>


<h3>Note</h3>

<p>The <abbr><span class="acronym">EMA</span></abbr>’s model assumes equal [<em>sic!</em>] intra-subject
variances of test and reference (like in 2×2×2 trials) &ndash;
even if proven false in one of the full replicate designs (were <em>both</em>
CV<sub>wT</sub> and
CV<sub>wR</sub> can be estimated).
Hence, amongst biostatisticians it is called the &lsquo;crippled model&rsquo;
because the replicative nature of the study is ignored.<br />
Conventional unscaled <abbr><span class="acronym">ABE</span></abbr> has to be employed for
C<sub>max</sub> (if widening of the
acceptance range is clinically not justifiable),
AUC<sub>0&ndash;t</sub>,
AUC<sub>0&ndash;72</sub> (immediate
release products) and
C<sub>max,ss</sub>,
C<sub>&tau;,ss</sub>,
<sub>partial</sub>AUC (if widening
of the acceptance range is clinically not justifiable), and
AUC<sub>0&ndash;t</sub>,
AUC<sub>0&ndash;&infin;</sub>,
AUC<sub>0&ndash;&tau;</sub>
(modified release products).
</p>


<h3>Author(s)</h3>

<p>Helmut Schütz
</p>


<h3>References</h3>

<p>European Medicines Agency, Committee for Medicinal Products for Human Use. <em>Guideline on the Investigation of Bioequivalence.</em> CPMP/EWP/QWP/1401/98 Rev. 1/ Corr **. London. 20 January 2010. <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf">online</a>
</p>
<p>European Medicines Agency, Committee for Medicinal Products for Human Use. <em>Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms.</em> EMA/CPMP/EWP/280/96 Corr1. London. 20 November 2014. <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmacokinetic-clinical-evaluation-modified-release-dosage-forms_en.pdf">online</a>
</p>


<h3>See Also</h3>


<table>
<tr>
 <td style="text-align: left;">
    <code><a href="#topic+method.A">method.A</a></code> </td><td style="text-align: left;"> evaluation for <abbr><span class="acronym">ABEL</span></abbr> by a fixed effects model (<abbr><span class="acronym">ANOVA</span></abbr>)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code><a href="#topic+method.B">method.B</a></code> </td><td style="text-align: left;"> evaluation for <abbr><span class="acronym">ABEL</span></abbr> by a linear mixed effects model
  </td>
</tr>

</table>



<h3>Examples</h3>

<pre><code class='language-R'>
# Importing from a CSV-file, using most of the defaults: variable
# separator comma, decimal separator period, print to file.
# Note: You must adapt the path-variables. The example reads from
# the data provided by the library. Write-permissions must be granted
# for 'path.out' in order to save the result file. Here the deafault
# (R's temporary folder) is used. If you don't know where it is,
# type tempdir() in the console.
path.in &lt;- paste0(find.package("replicateBE"), "/extdata/")
ABE(path.in = path.in, file = "DS", set = "02", ext = "csv")
# Should result in:
#   BE-limits          :  80.00% ... 125.00%
#   Confidence interval:  97.32% ... 107.46%  pass
#   Point estimate     : 102.26%
# Generate the data.frame of results (7-digits precision) and show
# in the console. Use an internal dataset.
x &lt;- ABE(details = TRUE, print = FALSE, data = rds02)
print(x, row.names = FALSE)

# Assuming a NTID and assess BE with narrower limits for one
# of the internal datasets.
ABE(data = rds02, theta1 = 0.90)
# Should result in:
#   BE-limits          :  90.00% ... 111.11%
#   Confidence interval:  97.32% ... 107.46%  pass
#   Point estimate     : 102.26%
</code></pre>

<hr>
<h2 id='method.A'>
Comparative BA-calculation for Average Bioequivalence with Expanding Limits by the EMA's 'Method A'
</h2><span id='topic+method.A'></span>

<h3>Description</h3>

<p>This function performs the required calculations for the mixed (or aggregate)
<abbr><span class="acronym">BE</span></abbr> decision via Average Bioequivalence with Expanding Limits
(<abbr><span class="acronym">ABEL</span></abbr>) based on <abbr><span class="acronym">ANOVA</span></abbr> (&lsquo;Method A&rsquo;) as recommended in <em>Annex I</em>.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>method.A(alpha = 0.05, path.in, path.out = tempdir(), file, set = "",
         ext, na = ".", sep = ",", dec = ".", logtrans = TRUE,
         regulator = "EMA", ola = FALSE, print = TRUE, details = FALSE,
         adjust = FALSE, verbose = FALSE, ask = FALSE,
         plot.bxp = FALSE, fence = 2, data = NULL)
</code></pre>


<h3>Arguments</h3>

<table>
<tr><td><code id="method.A_+3A_alpha">alpha</code></td>
<td>

<p>Type I Error (<abbr><span class="acronym">TIE</span></abbr>) probability (nominal level of the test).
Conventionally set to 0.05, resulting in a
100(1&nbsp;&ndash;&nbsp;2<em>&alpha;</em>)
confidence interval.
</p>
</td></tr>
<tr><td><code id="method.A_+3A_path.in">path.in</code></td>
<td>

<p>Path to the data file for import.
</p>
</td></tr>
<tr><td><code id="method.A_+3A_path.out">path.out</code></td>
<td>

<p>Path to save the result file if <code>print=TRUE</code>. You must have
write-permission to the folder. For simplicity your home folder <code style="white-space: pre;">&#8288;"~/"&#8288;</code> can be used.<br />
If missing, R’s standard temporary folder will be used.<br />
If a box plot of outliers should be saved (<code>plot.bxp = TRUE</code>), this path will be
used as well.
</p>
</td></tr>
<tr><td><code id="method.A_+3A_file">file</code></td>
<td>

<p>Name of the dataset for import (<em>without</em> extension). Must be
a string (<em>i.e.</em>, enclosed in single or double quotation marks).
</p>
</td></tr>
<tr><td><code id="method.A_+3A_set">set</code></td>
<td>

<p>Name of the sheet of an Excel-file (mandatory). Must be a string
(<em>i.e.</em>, enclosed in single or double quotation marks).
</p>
</td></tr>
<tr><td><code id="method.A_+3A_ext">ext</code></td>
<td>

<p>File-extension enclosed in single or double quotation marks.
Acceptable are <code style="white-space: pre;">&#8288;"csv"&#8288;</code> for character delimited
variables (<abbr><span class="acronym">CSV</span></abbr>) or <code style="white-space: pre;">&#8288;"xls"&#8288;</code>, <code style="white-space: pre;">&#8288;"xlsx"&#8288;</code> for Excel-files.<br />
The file-extension is not case-sensitive.
</p>
</td></tr>
<tr><td><code id="method.A_+3A_na">na</code></td>
<td>

<p>Character string denoting missing values. Acceptable are <code style="white-space: pre;">&#8288;"NA"&#8288;</code>
(not available), <code style="white-space: pre;">&#8288;"ND"&#8288;</code> (not determined), <code style="white-space: pre;">&#8288;"."&#8288;</code> (<abbr><span class="acronym">SAS</span></abbr>),
<code style="white-space: pre;">&#8288;"Missing"&#8288;</code> (Phoenix WinNonlin), and <code style="white-space: pre;">&#8288;""&#8288;</code> (<abbr><span class="acronym">Excel</span></abbr>;
empty cell). Missings will be converted to <code style="white-space: pre;">&#8288;NA&#8288;</code> in the imported
data. Defaults to <code style="white-space: pre;">&#8288;"."&#8288;</code>.
</p>
</td></tr>
<tr><td><code id="method.A_+3A_sep">sep</code></td>
<td>

<p>Variable separator in the <abbr><span class="acronym">CSV</span></abbr>-file. Acceptable are <code style="white-space: pre;">&#8288;","&#8288;</code>
(comma = <code style="white-space: pre;">&#8288;ASCII 44&#8288;</code>), <code style="white-space: pre;">&#8288;";"&#8288;</code> (semicolon = <code style="white-space: pre;">&#8288;ASCII 59&#8288;</code>),
and <code style="white-space: pre;">&#8288;"\t"&#8288;</code> (tabulator = <code style="white-space: pre;">&#8288;ASCII 9&#8288;</code>). Defaults to <code style="white-space: pre;">&#8288;","&#8288;</code>.
</p>
</td></tr>
<tr><td><code id="method.A_+3A_dec">dec</code></td>
<td>

<p>Decimal separator in the <abbr><span class="acronym">CSV</span></abbr>-file. Acceptable are <code style="white-space: pre;">&#8288;"."&#8288;</code>
(period = <code style="white-space: pre;">&#8288;ASCII 46&#8288;</code>) or <code style="white-space: pre;">&#8288;","&#8288;</code> (comma = <code style="white-space: pre;">&#8288;ASCII 44&#8288;</code>).
Defaults to <code style="white-space: pre;">&#8288;"."&#8288;</code>.
</p>
</td></tr>
<tr><td><code id="method.A_+3A_logtrans">logtrans</code></td>
<td>

<p>If <code>TRUE</code> (default) the raw data (provided in column <code style="white-space: pre;">&#8288;PK&#8288;</code>)
will be internally log-transformed and used in the calculations.
If <code>FALSE</code> the already log-transformed data (provided in the
column <code style="white-space: pre;">&#8288;logPK&#8288;</code>) will be used in the calculations.
</p>
</td></tr>
<tr><td><code id="method.A_+3A_regulator">regulator</code></td>
<td>

<p>Set regulatory conditions. If <code>"EMA"</code> (default) conventional ABEL will
be used. If <code>"GCC"</code> direct widening to 75.00&ndash;133.33% will be used if
<code>CVwR &gt; 30%</code>.
</p>
</td></tr>
<tr><td><code id="method.A_+3A_ola">ola</code></td>
<td>

<p>Defaults to <code>FALSE</code>. If <code>TRUE</code> an outlier analysis based
on the studentized and standardized (aka internally studentized) residuals
of the model estimating <code>CVwR</code> is performed.
</p>
</td></tr>
<tr><td><code id="method.A_+3A_print">print</code></td>
<td>

<p>If <code>TRUE</code> (default), the function prints its results to a
file. If <code>FALSE</code>, returns a data frame of results.
</p>
</td></tr>
<tr><td><code id="method.A_+3A_details">details</code></td>
<td>

<p>Defaults to <code>FALSE</code>. If <code>TRUE</code>, the function sends its
results in full precision to a data frame.
</p>
</td></tr>
<tr><td><code id="method.A_+3A_adjust">adjust</code></td>
<td>

<p>Defaults to <code>FALSE</code>.<br />
If <code>TRUE</code>, the empiric Type I Error (<em>TIE</em>) is evaluated via simulations
(by the function <a href="PowerTOST.html#topic+scABEL.ad">scABEL.ad</a> of library <code style="white-space: pre;">&#8288;PowerTOST&#8288;</code>). Currently
implemented designs are <code style="white-space: pre;">&#8288;2x2x4&#8288;</code>, <code style="white-space: pre;">&#8288;2x2x3&#8288;</code>, and
<code style="white-space: pre;">&#8288;2x3x3&#8288;</code>. If the <em>TIE</em> exceeds the nominal level of
the test <code>alpha</code>, <em>&alpha;</em>
is iteratively adjusted until
<em>TIE</em>&nbsp;=&nbsp;<em>&alpha;</em>&nbsp;&plusmn;&nbsp;10<sup>&ndash;6</sup>.<br />
If <code>ola = TRUE</code> and outlier(s) found &ndash; which lead to an always lower &ndash;
recalculated <code>CVwR</code>, the assessment is repeated for its value.
</p>
</td></tr>
<tr><td><code id="method.A_+3A_verbose">verbose</code></td>
<td>

<p>Defaults to <code>FALSE</code>. If <code>TRUE</code> the ANOVA-table is send to
the console. If <code>ola = TRUE</code> additional information about outliers
are shown.
</p>
</td></tr>
<tr><td><code id="method.A_+3A_ask">ask</code></td>
<td>

<p>Defaults to <code>FALSE</code>. If <code>TRUE</code> the user will be asked whether
an already existing result file (and if outliers are found, the box plot)
should be overwritten.
</p>
</td></tr>
<tr><td><code id="method.A_+3A_plot.bxp">plot.bxp</code></td>
<td>

<p>Only observed if <code>ola = TRUE</code> and at least one outlier is found.
If <code>FALSE</code> (default) the box plot will be shown in the graphics
device. If <code>TRUE</code> the box plot will be saved in <abbr><span class="acronym">PNG</span></abbr> format
to <code>path.out</code>.
</p>
</td></tr>
<tr><td><code id="method.A_+3A_fence">fence</code></td>
<td>

<p>Only observed if <code>ola = TRUE</code>. The limit for outlier detection as
a multiplier of the interquartile range. Defaults to 2. Less outliers
will be detected with higher values (not recommended).
</p>
</td></tr>
<tr><td><code id="method.A_+3A_data">data</code></td>
<td>

<p>Specification of one of the internal reference datasets (<code style="white-space: pre;">&#8288;rds01&#8288;</code> to  <code style="white-space: pre;">&#8288;rds30&#8288;</code>).
If given, the arguments <code style="white-space: pre;">&#8288;path.in&#8288;</code>, <code style="white-space: pre;">&#8288;file&#8288;</code>, <code style="white-space: pre;">&#8288;set&#8288;</code>, and <code style="white-space: pre;">&#8288;ext&#8288;</code> are
ignored. For its use see the examples.<br />
If not given, defaults to <code>NULL</code> (<em>i.e.</em>, import data
from a file).
</p>
</td></tr>
</table>


<h3>Details</h3>

<p>The model for the estimation of <code>CVwR</code> is<br />
<code>lm(log(PK) ~ sequence + subject%in%sequence + period, data = data[data$treatment == "R", ])</code><br />
where all effects are fixed.<br />
The model for the treatment comparison is<br />
<code>lm(log(PK) ~ sequence + subject%in%sequence + period + treatment, data = data)</code><br />
where all effects are fixed.<br /><br />
Tested designs
</p>

<ul>
<li><p> 4-period 2-sequence full replicates<br />
<code style="white-space: pre;">&#8288;TRTR | RTRT&#8288;</code><br />
<code style="white-space: pre;">&#8288;TRRT | RTTR&#8288;</code><br />
<code style="white-space: pre;">&#8288;TTRR | RRTT&#8288;</code>
</p>
</li>
<li><p> 2-period 4-sequence replicate<br />
<code style="white-space: pre;">&#8288;TR | RT | TT | RR &#8288;</code> (Balaam’s design)
</p>
</li>
<li><p> 4-period 4-sequence full replicates<br />
<code style="white-space: pre;">&#8288;TRTR | RTRT | TRRT | RTTR&#8288;</code><br />
<code style="white-space: pre;">&#8288;TRRT | RTTR | TTRR | RRTT&#8288;</code>
</p>
</li>
<li><p> 3-period 2-sequence full replicates<br />
<code style="white-space: pre;">&#8288;TRT | RTR&#8288;</code><br />
<code style="white-space: pre;">&#8288;TRR | RTT&#8288;</code>
</p>
</li>
<li><p> 3-period (partial) replicates<br />
<code style="white-space: pre;">&#8288;TRR | RTR | RRT&#8288;</code><br />
<code style="white-space: pre;">&#8288;TRR | RTR &#8288;</code> (extra-reference design)
</p>
</li></ul>

<p>Data structure
</p>

<ul>
<li><p> Columns must have the headers <code>subject</code>, <code>period</code>,
<code>sequence</code>, <code>treatment</code>, <code>PK</code>, and/or <code>logPK</code>.<br />
Any order of columns is acceptable.<br />
Uppercase and mixed case headers will be internally converted to lowercase headers.
</p>

<ul>
<li> <p><code>subject</code> must be integers or (any combination of) alphanumerics<br />
<code style="white-space: pre;">&#8288;[A-Z, a-z, -, _, #, 0-9]&#8288;</code>
</p>
</li>
<li> <p><code>period</code> must be integer numbers.
</p>
</li>
<li> <p><code>sequence</code> must be contained in the tested designs (numbers or
<em>e.g.</em>, <code style="white-space: pre;">&#8288;ABAB&#8288;</code> are not acceptable).
</p>
</li>
<li><p> The Test treatment must be coded <code>T</code> and the Reference <code>R</code>.
</p>
</li></ul>

</li></ul>



<h3>Value</h3>

<p>Prints results to a file if argument <code>print = TRUE</code> (default).<br />
If argument <code>print = FALSE</code>, returns a data frame with the elements:
</p>

<table>
<tr>
 <td style="text-align: left;">
    <code>Design</code> </td><td style="text-align: left;"> <em>e.g.</em>, TRTR|RTRT</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>Method</code> </td><td style="text-align: left;"> A</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>n</code> </td><td style="text-align: left;"> total number of subjects</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>nTT</code> </td><td style="text-align: left;"> number of subjects with two treatments of <code>T</code> (full replicates only)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>nRR</code> </td><td style="text-align: left;"> number of subjects with two treatments of <code>R</code></td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>Sub/seq</code> </td><td style="text-align: left;"> number of subjects per sequence</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>Miss/seq</code> </td><td style="text-align: left;"> if the design is unbalanced, number of missings per sequence</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>Miss/per</code> </td><td style="text-align: left;"> if the design is incomplete, number of missings per period</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>alpha</code> </td><td style="text-align: left;"> nominal level of the test</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>DF</code> </td><td style="text-align: left;"> degrees of freedom of the treatment comparison</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>CVwT(%)</code> </td><td style="text-align: left;"> intra-subject coefficient of variation of the test treatment (full replicates only)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>CVwR(%)</code> </td><td style="text-align: left;"> intra-subject coefficient of variation of the reference treatment</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>swT</code> </td><td style="text-align: left;"> intra-subject standard deviation of the test treatment (full replicates only)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>swR</code> </td><td style="text-align: left;"> intra-subject standard deviation of the reference treatment</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>sw.ratio</code> </td><td style="text-align: left;"> ratio of intra-subject deviations of <code>T</code> and <code>R</code> (full replicates only)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>sw.ratio.CL</code> </td><td style="text-align: left;"> upper confidence limit of <code>sw.ratio</code> (full replicates only)
  </td>
</tr>

</table>


<ul>
<li><p>If reference-scaling is applicable (<em>i.e.</em>, <code>CVwR(%)</code> &gt;30%):
</p>

<table>
<tr>
 <td style="text-align: left;">
      <code>L(%)</code> </td><td style="text-align: left;"> lower expanded limit of the acceptance range (AR)</td>
</tr>
<tr>
 <td style="text-align: left;">
      <code>U(%)</code> </td><td style="text-align: left;"> upper expanded limit of the acceptance range (AR)
    </td>
</tr>

</table>


</li>
<li><p>If reference-scaling is not applicable (<em>i.e.</em>, <code>CVwR(%)</code> &le;30%):
</p>

<table>
<tr>
 <td style="text-align: left;">
      <code>BE.lo(%)</code> </td><td style="text-align: left;"> lower limit of the conventional AR (<code style="white-space: pre;">&#8288; 80&#8288;</code>)</td>
</tr>
<tr>
 <td style="text-align: left;">
      <code>BE.hi(%)</code> </td><td style="text-align: left;"> upper limit of the conventional AR (<code style="white-space: pre;">&#8288;125&#8288;</code>)
    </td>
</tr>

</table>


</li></ul>


<table>
<tr>
 <td style="text-align: left;">
    <code>CL.lo(%)</code> </td><td style="text-align: left;"> lower confidence limit of the treatment comparison</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>CL.hi(%)</code> </td><td style="text-align: left;"> upper confidence limit of the treatment comparison</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>PE(%)</code> </td><td style="text-align: left;"> point estimate of the treatment comparison (aka <abbr><span class="acronym">GMR</span></abbr>)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>CI</code> </td><td style="text-align: left;"> assessment whether the 100(1&nbsp;&ndash;&nbsp;2<em>&alpha;</em>) <abbr><span class="acronym">CI</span></abbr> lies entirely within the acceptance range (<code style="white-space: pre;">&#8288;pass|fail&#8288;</code>)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>GMR</code> </td><td style="text-align: left;"> assessment whether the <abbr><span class="acronym">PE</span></abbr> lies entirely within the <abbr><span class="acronym">GMR</span></abbr>-restriction 80.00--125.00% (<code style="white-space: pre;">&#8288;pass|fail&#8288;</code>)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>BE</code> </td><td style="text-align: left;"> mixed (aggregate) assessment whether the study demonstrates bioequivalence (<code style="white-space: pre;">&#8288;pass|fail&#8288;</code>)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>log.half-width</code> </td><td style="text-align: left;"> half-width of the confidence interval in log-scale
  </td>
</tr>

</table>

<p>If <code>ola = TRUE</code> and at least one studentized outlier was detected:
</p>

<table>
<tr>
 <td style="text-align: left;">
    <code>outlier</code> </td><td style="text-align: left;"> outlying subject(s)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>CVwR.rec(%)</code> </td><td style="text-align: left;"> intra-subject coefficient of variation of <code>R</code>; recalculated after exclusion of outlier(s)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>swR.rec</code> </td><td style="text-align: left;"> intra-subject standard deviation of the reference treatment after exclusion of outlier(s)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>sw.ratio.rec</code> </td><td style="text-align: left;"> ratio of intra-subject standard deviations of <code>T</code> and <code>R</code> after exclusion of outlier(s); full replicates only</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>sw.ratio.rec.CL</code> </td><td style="text-align: left;"> upper confidence limit of <code>sw.ratio.rec</code> (full replicates only)
  </td>
</tr>

</table>


<ul>
<li><p>If reference-scaling is applicable (<em>i.e.</em>, <code>CVwR(%)</code> &gt;30):
</p>

<table>
<tr>
 <td style="text-align: left;">
      <code>L.rec(%)</code> </td><td style="text-align: left;"> recalculated lower expanded limit of the AR</td>
</tr>
<tr>
 <td style="text-align: left;">
      <code>U.rec(%)</code> </td><td style="text-align: left;"> recalculated upper expanded limit of the AR
    </td>
</tr>

</table>


</li>
<li><p>If reference-scaling is not applicable (<em>i.e.</em>, <code>CVwR(%)</code> &le;30):
</p>

<table>
<tr>
 <td style="text-align: left;">
      <code>BE.rec.lo(%)</code> </td><td style="text-align: left;"> lower limit of the conventional AR (<code style="white-space: pre;">&#8288; 80&#8288;</code>)</td>
</tr>
<tr>
 <td style="text-align: left;">
      <code>BE.rec.hi(%)</code> </td><td style="text-align: left;"> upper limit of the conventional AR (<code style="white-space: pre;">&#8288;125&#8288;</code>)
    </td>
</tr>

</table>


</li></ul>


<table>
<tr>
 <td style="text-align: left;">
    <code>CI.rec</code> </td><td style="text-align: left;"> assessment whether the 100(1&ndash;2&alpha;) <abbr><span class="acronym">CI</span></abbr> lies entirely within the new acceptance range (<code style="white-space: pre;">&#8288;pass|fail&#8288;</code>)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>GMR.rec</code> </td><td style="text-align: left;"> assessment whether the <abbr><span class="acronym">PE</span></abbr> lies entirely within the <abbr><span class="acronym">GMR</span></abbr>-restriction 80.00--125.00% (<code style="white-space: pre;">&#8288;pass|fail&#8288;</code>)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>BE.rec</code> </td><td style="text-align: left;"> mixed (aggregate) assessment whether the study demonstrates bioequivalence (<code style="white-space: pre;">&#8288;pass|fail&#8288;</code>)</td>
</tr>
<tr>
 <td style="text-align: left;">
  </td>
</tr>

</table>



<h3>Warning</h3>

<p>Files may contain a commentary header. If reading from a <abbr><span class="acronym">CSV</span></abbr>-file,
<em>each</em> line of the commentary header <em>must</em> start with <code style="white-space: pre;">&#8288;"# "&#8288;</code>
(hashmark space = <code style="white-space: pre;">&#8288;ASCII 35 ASCII 32&#8288;</code>). If reading from an Excel-file
all lines preceding the column headers are treated as a comment.
</p>


<h3>Clarification</h3>

<p>The &lsquo;ASCII line chart&rsquo; in the result file gives the confidence
limits with filled black squares and the point estimate as a white rhombus.
If a confidence limit exceeds the maximum possible expansion limit, it is
shown as a triangle. Expanded limits are given as double vertical lines.
Unscaled limits, the <abbr><span class="acronym">GMR</span></abbr> restriction, and 100% are given with
single vertical lines. The &lsquo;resolution&rsquo; is approximatelly 0.5% and
therefore, not all symbols might be shown. The <abbr><span class="acronym">CI</span></abbr> and <abbr><span class="acronym">PE</span></abbr> take presedence
over the limits and the expanded limits over unscaled ones.
</p>


<h3>Disclaimer</h3>

<p><em>Program offered for Use without any Guarantees and Absolutely No Warranty. No Liability is accepted for any Loss and Risk to Public Health Resulting from Use of this R-Code.</em>
</p>


<h3>Note</h3>

<p>The <abbr><span class="acronym">EMA</span></abbr>’s model specified as &lsquo;Method B&rsquo; in <em>Annex I</em> assumes
equal [<em>sic</em>] intra-subject variances of test and reference (like in
2&times;2&times;2
trials) &ndash; even if proven false in one of the full replicate designs (were
<em>both</em> <em>CV</em><sub>wT</sub> and
<em>CV</em><sub>wR</sub> can be estimated).
Hence, amongst biostatisticians it is called the &lsquo;crippled model&rsquo;
because the replicative nature of the study is ignored.<br />
The half-width of the <abbr><span class="acronym">CI</span></abbr> in log-scale allows a comparison of
methods (B <em>vs</em> A) where a higher value <em>might</em> point towards
a more conservative decision. In the provided reference datasets &ndash; with
one exception &ndash; the conclusion of <abbr><span class="acronym">BE</span></abbr> (based on the mixed
<abbr><span class="acronym">CI</span></abbr> and <abbr><span class="acronym">GMR</span></abbr> criteria) agrees between &lsquo;Method A&rsquo;
and &lsquo;Method B&rsquo;. However, for the highly incomplete dataset 14
&lsquo;Method A&rsquo; was <em>liberal</em> (passing by <abbr><span class="acronym">ANOVA</span></abbr> but
failing by the mixed effects model).<br /><br />
Reference-scaling is acceptable for <em>C</em><sub>max</sub> (immediate release products) and <em>C</em><sub>max,ss</sub>,
<em>C</em><sub>&tau;,ss</sub>, and
<sub>partial</sub><em>AUC</em> (modified release products). However, quoting the <abbr><span class="acronym">BE</span></abbr> guideline:<br />
<cite>The applicant should justify that the calculated intra-subject
variability is a reliable estimate and that it is not the result of
outliers.</cite><br />
Quoting the Q&amp;A on the Revised EMA Bioequivalence Guideline:<br />
<cite>... a study could be acceptable if the bioequivalence
requirements are met both including the outlier subject (using the
scaled average bioequivalence approach and the within-subject CV with
this subject) and after exclusion of the outlier (using the within-subject
CV without this subject).<br />
An outlier test is not an expectation of the medicines agencies but
outliers could be shown by a box plot. This would allow the medicines
agencies to compare the data between them.</cite><br /><br />
The <abbr><span class="acronym">EMA</span></abbr>’s method of reference-scaling for highly
variable drugs / drug products is currently recommended in other jurisdictions
as well (<em>e.g.</em>, the <abbr><span class="acronym">WHO</span></abbr>; <abbr><span class="acronym">ASEAN</span></abbr> States, Australia, Belarus,
Brazil, Chile, Egypt, the Eurasian Economic Union, the East African Community,
New Zealand, the Russian Federation).<br /><br />
In a pilot phase the <abbr><span class="acronym">WHO</span></abbr> accepted reference-scaling for <em>AUC</em> (4-period full replicate
studies are mandatory in order to assess the variability associated with each product).
It was an open issue how this assessment should be done. In Population Bioequivalence (<abbr><span class="acronym">PBE</span></abbr>)
and Individual Bioequivalence (<abbr><span class="acronym">IBE</span></abbr>) the
<em>s</em><sub>wT</sub>/<em>s</em><sub>wR</sub> ratio was assessed and similar
variability was concluded for a ratio within 0.667–1.500. However, the power
of comparing variabilities in a study designed to demonstrate <abbr><span class="acronym">ABE</span></abbr>
is low. This was one of the reasons why <abbr><span class="acronym">PBE</span></abbr> and <abbr><span class="acronym">IBE</span></abbr> were
not implemented in regulatory practice. An alternative approach is given in the
<abbr><span class="acronym">FDA</span></abbr>’s draft ANDA guidance. Variabilities are
considered comparable if the upper confidence limit of
<em>&sigma;</em><sub>wT</sub>/<em>&sigma;</em><sub>wR</sub> is less
than or equal to 2.5.<br />
In 2021 the requirement of comparing variabilities was lifted.
</p>


<h3>Author(s)</h3>

<p>Helmut Schütz, Michael Tomashevskiy, Detlew Labes
</p>


<h3>References</h3>

<p>European Medicines Agency, Committee for Medicinal Products for Human Use. <em>Guideline on the Investigation of Bioequivalence.</em> CPMP/EWP/QWP/1401/98 Rev. 1/ Corr **. London. 20 January 2010. <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf">online</a>
</p>
<p>European Generic and Biosimilar Medicines Association. 3<sup>rd</sup> <abbr><span class="acronym">EGA</span></abbr> Symposium on Bioequivalence. <em>Questions and Answers on the Revised <abbr><span class="acronym">EMA</span></abbr> Bioequivalence Guideline.</em> London. 1 June 2010. <a href="https://www.medicinesforeurope.com/wp-content/uploads/2016/03/EGA_BEQ_QA_WEB_QA_1_32.pdf">online</a>
</p>
<p>European Medicines Agency, Committee for Medicinal Products for Human Use. <em>Questions &amp; Answers: positions on specific questions addressed to the Pharmacokinetics Working Party (PKWP).</em> EMA/618604/2008 Rev. 13. London. 19 November 2015. <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/questions-answers-positions-specific-questions-addressed-pharmacokinetics-working-party_en.pdf">online</a>
</p>
<p>European Medicines Agency. <em>Clinical pharmacology and pharmacokinetics: questions and answers. 3.1 Which statistical method for the analysis of a bioequivalence study does the Agency recommend? Annex I</em>. EMA/582648/2016. London. 21 September 2016. <a href="https://www.ema.europa.eu/en/documents/other/31-annex-i-statistical-analysis-methods-compatible-ema-bioequivalence-guideline_en.pdf">online</a>
</p>
<p>Executive Board of the Health Ministers’ Council for GCC States. <em>The GCC Guidelines for Bioequivalence. Version 3.0.</em> May 2021. <a href="https://www.sfda.gov.sa/sites/default/files/2021-10/GCC_Guidelines_Bioequivalence.pdf">online</a>
</p>
<p>Health Canada. <em>Guidance Document. Conduct and Analysis of Comparative Bioavailability Studies.</em> Ottawa. 2018/06/08. <a href="https://www.canada.ca/content/dam/hc-sc/documents/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/bioavailability-bioequivalence/conduct-analysis-comparative.pdf">online</a>
</p>
<p>European Medicines Agency, Committee for Medicinal Products for Human Use. <em>Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms.</em> EMA/CPMP/EWP/280/96 Corr1. London. 20 November 2014. <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmacokinetic-clinical-evaluation-modified-release-dosage-forms_en.pdf">online</a>
</p>
<p>World Health Organization, Prequalification Team: medicines. <em>Guidance Document: Application of reference-scaled criteria for AUC in bioequivalence studies conducted for submission to PQTm.</em> Geneva. 22 November 2018. <a href="https://extranet.who.int/prequal/sites/default/files/documents/AUC_criteria_November2018.pdf">online</a>
</p>
<p>World Health Organization. <em>Application of reference-scaled criteria for AUC in bioequivalence studies conducted for submission to PQT/MED.</em> Geneva. 02 July 2021. <a href="https://extranet.who.int/pqweb/sites/default/files/documents/AUC_criteria_July2021.pdf">online</a>
</p>
<p>U.S. Food and Drug Administration, Center for Drug Evaluation and Research. <em>Draft Guidance for Industry. Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA.</em> August 2021. <a href="https://www.fda.gov/media/87219/Download">download</a>
</p>
<p>Labes D, Schütz H. <em>Inflation of Type I Error in the Evaluation of Scaled Average Bioequivalence, and a Method for its Control.</em> Pharm Res. 2016; 33(11): 2805&ndash;14. <a href="https://doi.org/10.1007/s11095-016-2006-1">doi:10.1007/s11095-016-2006-1</a>
</p>


<h3>See Also</h3>


<table>
<tr>
 <td style="text-align: left;">
    <code><a href="#topic+method.B">method.B</a></code> </td><td style="text-align: left;"> evaluation by a linear mixed effects model (subjects random)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code><a href="#topic+ABE">ABE</a></code> </td><td style="text-align: left;"> evaluation for conventional (unscaled) Average Bioequivalence
  </td>
</tr>

</table>



<h3>Examples</h3>

<pre><code class='language-R'># Importing from a CSV-file, using most of the defaults: variable
# separator colon, decimal separator period, no outlier-analyis,
# print to file.
# Note: You must adapt the path-variables. The example reads from
# the data provided by the library. Write-permissions must be granted
# for 'path.out' in order to save the result file. Here the default
# (R's temporary folder) is used. If you don't know where it is,
# type tempdir() in the console.

path.in  &lt;- paste0(find.package("replicateBE"), "/extdata/")
method.A(path.in = path.in, file = "DS", set = "01", ext = "csv")
# Should result in:
#   CVwT               :  35.16%
#   swT                :   0.34138
#   CVwR               :  46.96% (reference-scaling applicable)
#   swR                :   0.44645
#   Expanded limits    :  71.23% ... 140.40% [100exp(±0.760·swR)]
#   swT / swR          :   0.7647 (similar variabilities of T and R)
#   sw-ratio (upper CL):   0.9324 (comparable variabilities of T and R)
#   Confidence interval: 107.11% ... 124.89%  pass
#   Point estimate     : 115.66%              pass
#   Mixed (CI &amp; PE)    :                      pass
#
# Internal reference dataset 01 used and results to R's
# temporary folder. Additional outlier-analyis.
method.A(ola = TRUE, data = rds01)
# Should give the same as above. Additionally:
#   Outlier fence      :  2×IQR of studentized residuals.
#   Recalculation due to presence of 2 outliers (subj. 45|52)
#   CVwR (outl. excl.) :  32.16% (reference-scaling applicable)
#   swR (recalculated) :   0.31374
#   Expanded limits    :  78.79% ... 126.93% [100exp(±0.760·swR)]
#   swT / swR (recalc.):   1.0881 (similar variabilities of T and R)
#   sw-ratio (upper CL):   1.3282 (comparable variabilities of T and R)
#   Confidence interval: pass
#   Point estimate     : pass
#   Mixed (CI &amp; PE)    : pass
# Same dataset. Show information about outliers and the ANOVA-table.
method.A(ola = TRUE, print = FALSE, verbose = TRUE, data = rds01)
# Generate the data.frame of results (full precision) and show it
# in the console
x &lt;- method.A(ola = TRUE, details = TRUE, print = FALSE, data = rds01)
print(x, row.names = FALSE)
#
# Assess the Type I Error and iteratively adjust alpha if necessary.
# Not run: due to timing policy of CRAN for examples

method.A(adjust = TRUE, data = rds01)
# Should give in the result file:
#   Assessment of the empiric Type I Error (TIE); 1,000,000 studies simulated.
#     TIE not &gt; nominal 0.05; consumer risk is controlled.
#
# Same with recalculation based on outliers, iteratively adjust alpha
# if necessary

method.A(ola = TRUE, adjust = TRUE, data = rds01)
# Should give in the result file:
#   Assessment of the empiric Type I Error (TIE) based on original CVwR;
#   1,000,000 studies simulated.
#     TIE not &gt; nominal 0.05; consumer risk is controlled.
#   Assessment of the empiric Type I Error (TIE) based on recalculated CVwR;
#   1,000,000 studies in each of the 8 iterations simulated.
#     TIE for alpha 0.050000         : 0.07018
#     TIE for adjusted alpha 0.033416: 0.05000
#
# Repeat the evaluation with the adjusted alpha.

method.A(alpha = 0.033416, ola = TRUE, adjust = TRUE, data = rds01)
# Should give in the result file:
#   alpha              :   0.033416 (93.3168% CI)
#   Confidence interval: 106.16% ... 126.00%  pass
#   Point estimate     : 115.66%              pass
#   Mixed (CI &amp; PE)    :                      pass
#   Assessment based on recalculated CVwR 32.16%
#   Confidence interval: pass
#   Point estimate     : pass
#   Mixed (CI &amp; PE)    : pass
#   Assessment of the empiric Type I Error (TIE) based on original CVwR;
#   1,000,000 studies simulated.
#     TIE not &gt; nominal 0.05; consumer risk is controlled.
#   Assessment of empiric Type I Error (TIE) based on recalculated CVwR;
#   1,000,000 studies in each of the 8 iterations simulated.
#     TIE for alpha 0.033416         : 0.05000
#     TIE not &gt; nominal 0.05; consumer risk is controlled.
</code></pre>

<hr>
<h2 id='method.B'>
Comparative BA-calculation for Average Bioequivalence with Expanding Limits by the EMA's 'Method B'
</h2><span id='topic+method.B'></span>

<h3>Description</h3>

<p>This function performs the required calculations for the mixed (or aggregate)
<abbr><span class="acronym">BE</span></abbr> decision via Average Bioequivalence with Expanding Limits
(<abbr><span class="acronym">ABEL</span></abbr>) based on a linear mixed effects model with subjects as a
random effect (&lsquo;Method B&rsquo;) as specified in <em>Annex I</em>.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>method.B(alpha = 0.05, path.in, path.out = tempdir(), file, set = "",
         ext, na = ".", sep = ",", dec = ".", logtrans = TRUE,
         regulator = "EMA", ola = FALSE, print = TRUE, details = FALSE,
         verbose = FALSE, ask = FALSE, plot.bxp = FALSE, fence = 2,
         data = NULL, option = 2)
</code></pre>


<h3>Arguments</h3>

<table>
<tr><td><code id="method.B_+3A_alpha">alpha</code></td>
<td>

<p>Type I Error (<abbr><span class="acronym">TIE</span></abbr>) probability (nominal level of the test).
Conventionally set to 0.05, resulting in a
100(1&nbsp;&ndash;&nbsp;2<em>&alpha;</em>)
confidence interval.<br />
If <code>regulator = "HC"</code> and <code>alpha = 0.5</code> only the point estimate will be assessed (for highly variable <em>C</em><sub>max</sub> within 80.0&ndash;125.0%).
</p>
</td></tr>
<tr><td><code id="method.B_+3A_path.in">path.in</code></td>
<td>

<p>Path to the data file for import.
</p>
</td></tr>
<tr><td><code id="method.B_+3A_path.out">path.out</code></td>
<td>

<p>Path to save the result file if <code>print = TRUE</code>. You must have
write-permission to the folder. For simplicity your home folder <code style="white-space: pre;">&#8288;"~/"&#8288;</code> can be used.<br />
If missing, R’s standard temporary folder will be used.<br />
If a box plot of outliers should be saved (<code>plot.bxp = TRUE</code>), this path will be
used as well.
</p>
</td></tr>
<tr><td><code id="method.B_+3A_file">file</code></td>
<td>

<p>Name of the dataset for import (<em>without</em> extension). Must be
a string (<em>i.e.</em>, enclosed in single or double quotation marks).
</p>
</td></tr>
<tr><td><code id="method.B_+3A_set">set</code></td>
<td>

<p>Name of the sheet of an Excel-file (mandatory). Must be a string
(<em>i.e.</em>, enclosed in single or double quotation marks).
</p>
</td></tr>
<tr><td><code id="method.B_+3A_ext">ext</code></td>
<td>

<p>File-extension enclosed in single or double quotation marks.
Acceptable are <code style="white-space: pre;">&#8288;"csv"&#8288;</code> for character delimited
variables (<abbr><span class="acronym">CSV</span></abbr>) or <code style="white-space: pre;">&#8288;"xls"&#8288;</code>, <code style="white-space: pre;">&#8288;"xlsx"&#8288;</code> for Excel-files.<br />
The file-extension is not case-sensitive.
</p>
</td></tr>
<tr><td><code id="method.B_+3A_na">na</code></td>
<td>

<p>Character string denoting missing values. Acceptable are <code style="white-space: pre;">&#8288;"NA"&#8288;</code>
(not available), <code style="white-space: pre;">&#8288;"ND"&#8288;</code> (not determined), <code style="white-space: pre;">&#8288;"."&#8288;</code> (<abbr><span class="acronym">SAS</span></abbr>),
<code style="white-space: pre;">&#8288;"Missing"&#8288;</code> (Phoenix WinNonlin), and <code style="white-space: pre;">&#8288;""&#8288;</code> (<abbr><span class="acronym">Excel</span></abbr>;
empty cell). Missings will be converted to <code style="white-space: pre;">&#8288;NA&#8288;</code> in the imported
data. Defaults to <code style="white-space: pre;">&#8288;"."&#8288;</code>.
</p>
</td></tr>
<tr><td><code id="method.B_+3A_sep">sep</code></td>
<td>

<p>Variable separator in the <abbr><span class="acronym">CSV</span></abbr>-file. Acceptable are <code style="white-space: pre;">&#8288;","&#8288;</code>
(comma = <code style="white-space: pre;">&#8288;ASCII 44&#8288;</code>), <code style="white-space: pre;">&#8288;";"&#8288;</code> (semicolon = <code style="white-space: pre;">&#8288;ASCII 59&#8288;</code>), and
<code style="white-space: pre;">&#8288;"\t"&#8288;</code> (tabulator = <code style="white-space: pre;">&#8288;ASCII 9&#8288;</code>). Defaults to <code style="white-space: pre;">&#8288;","&#8288;</code>.
</p>
</td></tr>
<tr><td><code id="method.B_+3A_dec">dec</code></td>
<td>

<p>Decimal separator in the <abbr><span class="acronym">CSV</span></abbr>-file. Acceptable are
<code style="white-space: pre;">&#8288;"."&#8288;</code> (period = <code style="white-space: pre;">&#8288;ASCII 46&#8288;</code>) or <code style="white-space: pre;">&#8288;","&#8288;</code> (comma = <code style="white-space: pre;">&#8288;ASCII 44&#8288;</code>).
Defaults to <code style="white-space: pre;">&#8288;"."&#8288;</code>.
</p>
</td></tr>
<tr><td><code id="method.B_+3A_logtrans">logtrans</code></td>
<td>

<p>If <code>TRUE</code> (default) the raw data (provided in column <code style="white-space: pre;">&#8288;PK&#8288;</code>)
will be internally log-transformed and used in the calculations. If
<code>FALSE</code> the already log-transformed data (provided in the column
<code style="white-space: pre;">&#8288;logPK&#8288;</code>) will be used in the calculations.
</p>
</td></tr>
<tr><td><code id="method.B_+3A_regulator">regulator</code></td>
<td>

<p>Set regulatory conditions. If <code>"EMA"</code> (default) conventional ABEL will
be used. If <code>"HC"</code> Health Canada’s upper cap of scaling (~57.4%)
will be applied. If <code>"GCC"</code> direct widening to 75.00&ndash;133.33% will be
used if <code>CVwR &gt; 30%</code>.
</p>
</td></tr>
<tr><td><code id="method.B_+3A_ola">ola</code></td>
<td>

<p>Defaults to <code>FALSE</code>. If <code>TRUE</code> an outlier analysis based
on the studentized and standardized (aka internally studentized) residuals
of the model estimating <code>CVwR</code> is performed.
</p>
</td></tr>
<tr><td><code id="method.B_+3A_print">print</code></td>
<td>

<p>If <code>TRUE</code> (default), the function prints its results to a file.
If <code>FALSE</code>, returns a data frame of results.
</p>
</td></tr>
<tr><td><code id="method.B_+3A_details">details</code></td>
<td>

<p>Defaults to <code>FALSE</code>. If <code>TRUE</code>, the function sends its
results in full precision to a data frame.
</p>
</td></tr>
<tr><td><code id="method.B_+3A_verbose">verbose</code></td>
<td>

<p>Defaults to <code>FALSE</code>. If <code>TRUE</code> the model-table is send to
the console. If <code>ola = TRUE</code> additional information about outliers
are shown.
</p>
</td></tr>
<tr><td><code id="method.B_+3A_ask">ask</code></td>
<td>

<p>Defaults to <code>FALSE</code>. If <code>TRUE</code> the user will be asked whether
an already existing result file (and if outliers are found, the box plot)
should be overwritten.
</p>
</td></tr>
<tr><td><code id="method.B_+3A_plot.bxp">plot.bxp</code></td>
<td>

<p>Only observed if <code>ola = TRUE</code> and at least one outlier is found.
If <code>FALSE</code> (default) the box plot will be shown in the graphics
device. If <code>TRUE</code> the box plot will be saved in <abbr><span class="acronym">PNG</span></abbr> format
to <code>path.out</code>.
</p>
</td></tr>
<tr><td><code id="method.B_+3A_fence">fence</code></td>
<td>

<p>Only observed if <code>ola = TRUE</code>. The limit for outlier detection as
a multiplier of the interquartile range. Defaults to 2. Less outliers
will be detected with higher values (not recommended).
</p>
</td></tr>
<tr><td><code id="method.B_+3A_data">data</code></td>
<td>

<p>Specification of one of the internal reference datasets (<code style="white-space: pre;">&#8288;rds01&#8288;</code> to <code style="white-space: pre;">&#8288;rds30&#8288;</code>).
If given, the arguments <code style="white-space: pre;">&#8288;path.in&#8288;</code>, <code style="white-space: pre;">&#8288;file&#8288;</code>, <code style="white-space: pre;">&#8288;set&#8288;</code>, and <code style="white-space: pre;">&#8288;ext&#8288;</code> are
ignored. For its use see the examples.<br />
If not given, defaults to <code>NULL</code> (<em>i.e.</em>, import data
from a file).
</p>
</td></tr>
<tr><td><code id="method.B_+3A_option">option</code></td>
<td>

<p>If <code>2</code> (default), the model will be evaluated by <code style="white-space: pre;">&#8288;lme()&#8288;</code> of
package <code style="white-space: pre;">&#8288;nlme&#8288;</code>. The degrees of freedom of the treatment comparison
will be equivalent to <abbr><span class="acronym">SAS</span></abbr>’ <code style="white-space: pre;">&#8288;DDFM=CONTAIN&#8288;</code> and
Phoenix WinNonlin’s <code style="white-space: pre;">&#8288;Residual&#8288;</code>.<br />
If <code>1</code> or <code>3</code>, the model will be evaluated by <code style="white-space: pre;">&#8288;lmer()&#8288;</code> of package
<code style="white-space: pre;">&#8288;lmerTest&#8288;</code>. With <code>1</code> the degrees of freedom of the treatment comparison
will be equivalent to <abbr><span class="acronym">SAS</span></abbr>’ <code style="white-space: pre;">&#8288;DDFM=SATTERTHWAITE&#8288;</code>
and Phoenix WinNonlin’s <code style="white-space: pre;">&#8288;Satterthwaite&#8288;</code>.<br />
<code>3</code> uses the Kenward-Roger approximation equivalent to Stata’s
<code style="white-space: pre;">&#8288;dfm=Kenward Roger (EIM)&#8288;</code>.<br />
If <code style="white-space: pre;">&#8288;regulator = "HC"&#8288;</code>, only <code>1</code> or <code>3</code> are supported.
</p>
</td></tr>
</table>


<h3>Details</h3>

<p>The model for the estimation of <code>CVwR</code> is<br />
<code>lm(log(PK) ~ sequence + subject%in%sequence + period, data = data[data$treatment == "R", ])</code><br />
where all effects are fixed.<br />
The model for the treatment comparison is with the default <code>option=2</code><br />
<code>lme(log(PK) ~ sequence +  period + treatment, random = ~1|subject, data = data)</code><br />
and with <code>option=1</code>, <code>option=3</code><br />
<code>lmer(log(PK) ~ sequence + period + treatment + (1|subject), data = data)</code><br />
where <code>sequence</code>, <code>period</code>, and <code>treatment</code> are fixed effects and <code>subject(sequence)</code> is a random effect.<br /><br />
Tested designs
</p>

<ul>
<li><p> 4-period 2-sequence full replicates<br />
<code style="white-space: pre;">&#8288;TRTR | RTRT&#8288;</code><br />
<code style="white-space: pre;">&#8288;TRRT | RTTR&#8288;</code><br />
<code style="white-space: pre;">&#8288;TTRR | RRTT&#8288;</code>
</p>
</li>
<li><p> 2-period 4-sequence replicate<br />
<code style="white-space: pre;">&#8288;TR | RT | TT | RR &#8288;</code> (Balaam’s design)
</p>
</li>
<li><p> 4-period 4-sequence full replicates<br />
<code style="white-space: pre;">&#8288;TRTR | RTRT | TRRT | RTTR&#8288;</code><br />
<code style="white-space: pre;">&#8288;TRRT | RTTR | TTRR | RRTT&#8288;</code>
</p>
</li>
<li><p> 3-period 2-sequence full replicates<br />
<code style="white-space: pre;">&#8288;TRT | RTR&#8288;</code><br />
<code style="white-space: pre;">&#8288;TRR | RTT&#8288;</code>
</p>
</li>
<li><p> 3-period (partial) replicates<br />
<code style="white-space: pre;">&#8288;TRR | RTR | RRT&#8288;</code><br />
<code style="white-space: pre;">&#8288;TRR | RTR &#8288;</code> (extra-reference design)
</p>
</li></ul>

<p>Data structure
</p>

<ul>
<li><p> Columns must have the headers <code>subject</code>, <code>period</code>,
<code>sequence</code>, <code>treatment</code>, <code>PK</code>, and/or <code>logPK</code>.<br />
Any order of columns is acceptable.<br />
Uppercase and mixed case headers will be internally converted to lowercase headers.
</p>

<ul>
<li> <p><code>subject</code> must be integer numbers or (any combination of) alphanumerics<br />
<code style="white-space: pre;">&#8288;[A-Z, a-z, -, _, #, 0-9]&#8288;</code>
</p>
</li>
<li> <p><code>period</code> must be integer numbers.
</p>
</li>
<li> <p><code>sequence</code> must be contained in the tested designs (numbers or <em>e.g.</em>, <code>ABAB</code> are not acceptable).
</p>
</li>
<li><p> The Test treatment must be coded <code>T</code> and the Reference <code>R</code>.
</p>
</li></ul>

</li></ul>



<h3>Value</h3>

<p>Prints results to a file if argument <code>print = TRUE</code> (default).<br />
If argument <code>print = FALSE</code>, returns a data.frame with the elements:
</p>

<table>
<tr>
 <td style="text-align: left;">
    <code>Design</code> </td><td style="text-align: left;"> <em>e.g.</em>, TRTR|RTRT</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>Method</code> </td><td style="text-align: left;"> B-<code>option</code> (<code>1</code>, <code>2</code>, or <code>3</code>)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>n</code> </td><td style="text-align: left;"> total number of subjects</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>nTT</code> </td><td style="text-align: left;"> number of subjects with two treatments of <code>T</code> (full replicates only)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>nRR</code> </td><td style="text-align: left;"> number of subjects with two treatments of <code>R</code></td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>Sub/seq</code> </td><td style="text-align: left;"> number of subjects per sequence</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>Miss/seq</code> </td><td style="text-align: left;"> if the design is unbalanced, number of missings per sequence</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>Miss/per</code> </td><td style="text-align: left;"> if the design is incomplete, number of missings per period</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>alpha</code> </td><td style="text-align: left;"> nominal level of the test</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>DF</code> </td><td style="text-align: left;"> degrees of freedom of the treatment comparison</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>CVwT(%)</code> </td><td style="text-align: left;"> intra-subject coefficient of variation of the test treatment (full replicates only)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>CVwR(%)</code> </td><td style="text-align: left;"> intra-subject coefficient of variation of the reference treatment</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>swT</code> </td><td style="text-align: left;"> intra-subject standard deviation of the test treatment (full replicates only)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>swR</code> </td><td style="text-align: left;"> intra-subject standard deviation of the reference treatment</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>sw.ratio</code> </td><td style="text-align: left;"> ratio of intra-subject deviations of <code>T</code> and <code>R</code> (full replicates only)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>sw.ratio.CL</code> </td><td style="text-align: left;"> upper confidence limit of <code>sw.ratio</code> (full replicates only)
  </td>
</tr>

</table>


<ul>
<li><p>If reference-scaling is applicable (<em>i.e.</em>, <code>CVwR(%)</code> &gt;30):
</p>

<table>
<tr>
 <td style="text-align: left;">
      <code>L(%)</code> </td><td style="text-align: left;"> lower expanded limit of the acceptance range (AR)</td>
</tr>
<tr>
 <td style="text-align: left;">
      <code>U(%)</code> </td><td style="text-align: left;"> upper expanded limit of the acceptance range (AR)
    </td>
</tr>

</table>


</li>
<li><p>If reference-scaling is not applicable (<em>i.e.</em>, &le;30):
</p>

<table>
<tr>
 <td style="text-align: left;">
      <code>BE.lo(%)</code> </td><td style="text-align: left;"> lower limit of the conventional AR (<code style="white-space: pre;">&#8288; 80&#8288;</code>)</td>
</tr>
<tr>
 <td style="text-align: left;">
      <code>BE.hi(%)</code> </td><td style="text-align: left;"> upper limit of the conventional AR (<code style="white-space: pre;">&#8288;125&#8288;</code>)
    </td>
</tr>

</table>


</li></ul>


<table>
<tr>
 <td style="text-align: left;">
    <code>CL.lo(%)</code> </td><td style="text-align: left;"> lower confidence limit of the treatment comparison</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>CL.hi(%)</code> </td><td style="text-align: left;"> upper confidence limit of the treatment comparison</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>PE(%)</code> </td><td style="text-align: left;"> point estimate of the treatment comparison (aka <abbr><span class="acronym">GMR</span></abbr>)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>CI</code> </td><td style="text-align: left;"> assessment whether the 100(1&nbsp;&ndash;&nbsp;2<em>&alpha;</em>) <abbr><span class="acronym">CI</span></abbr> lies entirely within the acceptance range (<code style="white-space: pre;">&#8288;pass|fail&#8288;</code>)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>GMR</code> </td><td style="text-align: left;"> assessment whether the <abbr><span class="acronym">PE</span></abbr> lies entirely within the <abbr><span class="acronym">GMR</span></abbr>-restriction 80.00--125.00% (<code style="white-space: pre;">&#8288;pass|fail&#8288;</code>)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>BE</code> </td><td style="text-align: left;"> mixed (aggregate) assessment whether the study demonstrates bioequivalence (<code style="white-space: pre;">&#8288;pass|fail&#8288;</code>)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>log.half-width</code> </td><td style="text-align: left;"> half-width of the confidence interval in log-scale
  </td>
</tr>

</table>

<p>If <code>ola = TRUE</code> and at least one studentized outlier was detected:
</p>

<table>
<tr>
 <td style="text-align: left;">
    <code>outlier</code> </td><td style="text-align: left;"> outlying subject(s)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>CVwR.rec(%)</code> </td><td style="text-align: left;"> intra-subject coefficient of variation of <code>R</code>; recalculated after exclusion of outlier(s)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>swR.rec</code> </td><td style="text-align: left;"> intra-subject standard deviation of the reference treatment after exclusion of outlier(s)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>sw.ratio.rec</code> </td><td style="text-align: left;"> ratio of intra-subjectstandard deviations of <code>T</code> and <code>R</code> after exclusion of outlier(s); full replicates only</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>sw.ratio.rec.CL</code> </td><td style="text-align: left;"> upper confidence limit of <code>sw.ratio.rec</code> (full replicates only)
  </td>
</tr>

</table>


<ul>
<li><p>If reference-scaling is applicable (<em>i.e.</em>, <code>CVwR.rec(%)</code> &gt;30):
</p>

<table>
<tr>
 <td style="text-align: left;">
      <code>L.rec(%)</code> </td><td style="text-align: left;"> recalculated lower expanded limit of the AR</td>
</tr>
<tr>
 <td style="text-align: left;">
      <code>U.rec(%)</code> </td><td style="text-align: left;"> recalculated upper expanded limit of the AR
    </td>
</tr>

</table>


</li>
<li><p>If reference-scaling is not applicable (<em>i.e.</em>, <code>CVwR.rec(%)</code> &le;30):
</p>

<table>
<tr>
 <td style="text-align: left;">
      <code>BE.rec.lo(%)</code> </td><td style="text-align: left;"> lower limit of the conventional AR (<code style="white-space: pre;">&#8288; 80&#8288;</code>)</td>
</tr>
<tr>
 <td style="text-align: left;">
      <code>BE.rec.hi(%)</code> </td><td style="text-align: left;"> upper limit of the conventional AR (<code style="white-space: pre;">&#8288;125&#8288;</code>)
    </td>
</tr>

</table>


</li></ul>


<table>
<tr>
 <td style="text-align: left;">
    <code>CI.rec</code> </td><td style="text-align: left;"> assessment whether the 100(1&ndash;2&alpha;) <abbr><span class="acronym">CI</span></abbr> lies entirely within the new acceptance range (<code style="white-space: pre;">&#8288;pass|fail&#8288;</code>)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>GMR.rec</code> </td><td style="text-align: left;"> assessment whether the <abbr><span class="acronym">PE</span></abbr> lies entirely within the <abbr><span class="acronym">GMR</span></abbr>-restriction 80.00--125.00% (<code style="white-space: pre;">&#8288;pass|fail&#8288;</code>)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code>BE.rec</code> </td><td style="text-align: left;"> mixed (aggregate) assessment whether the study demonstrates bioequivalence (<code style="white-space: pre;">&#8288;pass|fail&#8288;</code>)</td>
</tr>
<tr>
 <td style="text-align: left;">
  </td>
</tr>

</table>



<h3>Warning</h3>

<p>Files may contain a commentary header. If reading from a <abbr><span class="acronym">CSV</span></abbr>-file,
<em>each</em> line of the commentary header <em>must</em> start with <code style="white-space: pre;">&#8288;"# "&#8288;</code>
(hashmark space = <code style="white-space: pre;">&#8288;ASCII 35 ASCII 32&#8288;</code>). If reading from an Excel-file
all lines preceding the column headers are treated as a comment.
</p>


<h3>Clarification</h3>

<p>The &lsquo;ASCII line chart&rsquo; in the result file gives the confidence
limits with filled black squares and the point estimate as a white rhombus.
If a confidence limit exceeds the maximum possible expansion limit, it is
shown as a triangle. Expanded limits are given as double vertical lines.
Unscaled limits, the <abbr><span class="acronym">GMR</span></abbr> restriction, and 100% are given with
single vertical lines. The &lsquo;resolution&rsquo; is approximatelly 0.5% and
therefore, not all symbols might be shown. The <abbr><span class="acronym">CI</span></abbr> and <abbr><span class="acronym">PE</span></abbr> take presedence
over the limits and the expanded limits over unscaled ones.
</p>


<h3>Disclaimer</h3>

<p><em>Program offered for Use without any Guarantees and Absolutely No Warranty. No Liability is accepted for any Loss and Risk to Public Health Resulting from Use of this R-Code.</em>
</p>


<h3>Note</h3>

<p>The <abbr><span class="acronym">EMA</span></abbr>’s model specified as &lsquo;Method B&rsquo; in <em>Annex I</em> assumes
equal [<em>sic</em>] intra-subject variances of test and reference (like in
2&times;2&times;2
trials) &ndash; even if proven false in one of the full replicate designs (were
<em>both</em> <em>CV</em><sub>wT</sub> and
<em>CV</em><sub>wR</sub> can be estimated).
Hence, amongst biostatisticians it is called the &ldquo;crippled model&rdquo;
because the replicative nature of the study is ignored.<br />
The method for calculating the degrees of freedom is not specified in the
<abbr><span class="acronym">SAS</span></abbr> code provided by the <abbr><span class="acronym">EMA</span></abbr> in <em>Annex I</em>. Hence,
the default in <code>PROC MIXED</code>, namely <code>DDFM=CONTAIN</code> is applied.<br />
For incomplete data (<em>i.e.</em>, missing periods) Satterthwaite’s
approximation of the degrees of freedom (<code>option = 1</code>) or Kenward-Roger (<code>option = 3</code>)
might be better choices &ndash; if stated as such in the statistical analysis plan.<br />
The half-width of the confidence interval in log-scale allows a comparison of methods (B
<em>v.s.</em> A) or options (2 <em>v.s.</em> 1). A higher value <em>might</em>
point towards a more conservative decision. Quoting the Q&amp;A-document:<br />
<cite>A simple linear mixed model, which assumes identical within-subject
variability (Method B), may be acceptable as long as results obtained
with the two methods do not lead to different regulatory decisions.
However, in borderline cases [...] additional analysis using Method
A might be required.</cite><br />
In the provided reference datasets &ndash; with one exception &ndash; the conclusion
of <abbr><span class="acronym">BE</span></abbr> (based on the mixed <abbr><span class="acronym">CI</span></abbr> and <abbr><span class="acronym">GMR</span></abbr> criteria)
agrees between &lsquo;Method A&rsquo; and &lsquo;Method B&rsquo;. However, for the
highly incomplete dataset 14 &lsquo;Method A&rsquo; was <em>liberal</em> (passing
by <abbr><span class="acronym">ANOVA</span></abbr> but failing by the mixed effects model).<br /><br />
Reference-scaling is acceptable for <em>C</em><sub>max</sub> (immediate release products) and <em>C</em><sub>max,ss</sub>,
<em>C</em><sub>&tau;,ss</sub>, and
<sub>partial</sub><em>AUC</em> (modified release products). However, quoting the <abbr><span class="acronym">BE</span></abbr> guideline:<br />
<cite>The applicant should justify that the calculated intra-subject
variability is a reliable estimate and that it is not the result of
outliers.</cite><br />
Quoting the Q&amp;A on the Revised EMA Bioequivalence Guideline:<br />
<cite>... a study could be acceptable if the bioequivalence
requirements are met both including the outlier subject (using the
scaled average bioequivalence approach and the within-subject CV with
this subject) and after exclusion of the outlier (using the within-subject
CV without this subject).<br />
An outlier test is not an expectation of the medicines agencies but
outliers could be shown by a box plot. This would allow the medicines
agencies to compare the data between them.</cite><br /><br />
The <abbr><span class="acronym">EMA</span></abbr>’s method of reference-scaling for highly
variable drugs / drug products is currently recommended in other jurisdictions
as well (<em>e.g.</em>, the <abbr><span class="acronym">WHO</span></abbr>; <abbr><span class="acronym">ASEAN</span></abbr> States, Australia,
Belarus, Brazil, Chile, Egypt, the Eurasian Economic Union, the East African Community,
New Zealand, the Russian Federation).<br /><br />
Health Canada’s variant of ABEL (upper cap of scaling ~57.4% limiting the expansion
at 67.7&ndash;150.0%) is only approximate because a mixed-effects model would be required.<br /><br />
In a pilot phase the <abbr><span class="acronym">WHO</span></abbr> accepted reference-scaling for <em>AUC</em> (4-period full replicate
studies are mandatory in order to assess the variability associated with each product).
It was an open issue how this assessment should be done. In Population Bioequivalence (<abbr><span class="acronym">PBE</span></abbr>)
and Individual Bioequivalence (<abbr><span class="acronym">IBE</span></abbr>) the
<em>s</em><sub>wT</sub>/<em>s</em><sub>wR</sub> ratio was assessed and similar
variability was concluded for a ratio within 0.667&ndash;1.500. However, the power
of comparing variabilities in a study designed to demonstrate <abbr><span class="acronym">ABE</span></abbr>
is low. This was one of the reasons why <abbr><span class="acronym">PBE</span></abbr> and <abbr><span class="acronym">IBE</span></abbr> were
not implemented in regulatory practice. An alternative approach is given in the
<abbr><span class="acronym">FDA</span></abbr>’s draft ANDA guidance. Variabilities are
considered comparable if the upper confidence limit of
<em>&sigma;</em><sub>wT</sub>/<em>&sigma;</em><sub>wR</sub> is less
than or equal to 2.5.<br />
In 2021 the requirement of comparing variabilities was lifted by the <abbr><span class="acronym">WHO</span></abbr>.
</p>


<h3>Author(s)</h3>

<p>Helmut Schütz, Michael Tomashevskiy, Detlew Labes
</p>


<h3>References</h3>

<p>European Medicines Agency, Committee for Medicinal Products for Human Use. <em>Guideline on the Investigation of Bioequivalence.</em> CPMP/EWP/QWP/1401/98 Rev. 1/ Corr **. London. 20 January 2010. <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf">online</a>
</p>
<p>European Generic and Biosimilar Medicines Association. 3<sup>rd</sup> <abbr><span class="acronym">EGA</span></abbr> Symposium on Bioequivalence. <em>Questions and Answers on the Revised <abbr><span class="acronym">EMA</span></abbr> Bioequivalence Guideline.</em> London. 1 June 2010. <a href="https://www.medicinesforeurope.com/wp-content/uploads/2016/03/EGA_BEQ_QA_WEB_QA_1_32.pdf">online</a>
</p>
<p>European Medicines Agency, Committee for Medicinal Products for Human Use. <em>Questions &amp; Answers: positions on specific questions addressed to the Pharmacokinetics Working Party (PKWP).</em> EMA/618604/2008 Rev. 13. London. 19 November 2015. <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/questions-answers-positions-specific-questions-addressed-pharmacokinetics-working-party_en.pdf">online</a>
</p>
<p>European Medicines Agency. <em>Clinical pharmacology and pharmacokinetics: questions and answers. 3.1 Which statistical method for the analysis of a bioequivalence study does the Agency recommend? Annex I</em>. EMA/582648/2016. London. 21 September 2016. <a href="https://www.ema.europa.eu/en/documents/other/31-annex-i-statistical-analysis-methods-compatible-ema-bioequivalence-guideline_en.pdf">online</a>
</p>
<p>Executive Board of the Health Ministers’ Council for GCC States. <em>The GCC Guidelines for Bioequivalence. Version 3.0.</em> May 2021. <a href="https://www.sfda.gov.sa/sites/default/files/2021-10/GCC_Guidelines_Bioequivalence.pdf">online</a>
</p>
<p>Health Canada. <em>Guidance Document. Conduct and Analysis of Comparative Bioavailability Studies.</em> Ottawa. 2018/06/08. <a href="https://www.canada.ca/content/dam/hc-sc/documents/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/bioavailability-bioequivalence/conduct-analysis-comparative.pdf">online</a>
</p>
<p>European Medicines Agency, Committee for Medicinal Products for Human Use. <em>Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms.</em> EMA/CPMP/EWP/280/96 Corr1. London. 20 November 2014. <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmacokinetic-clinical-evaluation-modified-release-dosage-forms_en.pdf">online</a>
</p>
<p>World Health Organization, Prequalification Team: medicines. <em>Guidance Document: Application of reference-scaled criteria for AUC in bioequivalence studies conducted for submission to PQTm.</em> Geneva. 22 November 2018. <a href="https://extranet.who.int/prequal/sites/default/files/documents/AUC_criteria_November2018.pdf">online</a>
</p>
<p>World Health Organization. <em>Application of reference-scaled criteria for AUC in bioequivalence studies conducted for submission to PQT/MED.</em> Geneva. 02 July 2021. <a href="https://extranet.who.int/pqweb/sites/default/files/documents/AUC_criteria_July2021.pdf">online</a>
</p>
<p>U.S. Food and Drug Administration, Center for Drug Evaluation and Research. <em>Draft Guidance for Industry. Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA.</em> August 2021. <a href="https://www.fda.gov/media/87219/Download">download</a>
</p>


<h3>See Also</h3>


<table>
<tr>
 <td style="text-align: left;">
    <code><a href="#topic+method.A">method.A</a></code> </td><td style="text-align: left;"> evaluation by a fixed effects model (<abbr><span class="acronym">ANOVA</span></abbr>)</td>
</tr>
<tr>
 <td style="text-align: left;">
    <code><a href="#topic+ABE">ABE</a></code> </td><td style="text-align: left;"> evaluation for conventional (unscaled) Average Bioequivalence
  </td>
</tr>

</table>



<h3>Examples</h3>

<pre><code class='language-R'>
# Importing from a CSV-file, using most of the defaults: variable
# separator colon, decimal separator period, no outlier-analyis,
# print to file.
# Note: You must adapt the path-variables. The example reads from
# the data provided by the library. Write-permissions must be granted
# for 'path.out' in order to save the result file. Here the default
# (R's temporary folder) is used. If you don't know where it is,
# type tempdir() in the console.
path.in &lt;- paste0(find.package("replicateBE"), "/extdata/")
method.B(path.in = path.in, file = "DS", set = "01", ext = "csv")
# Should result in:
#   CVwT               :  35.16%
#   swT                :   0.34138
#   CVwR               :  46.96% (reference-scaling applicable)
#   swR                :   0.44645
#   Expanded limits    :  71.23% ... 140.40% [100exp(±0.760·swR)]
#   swT / swR          :   0.7647 (similar variabilities of T and R)
#   sw-ratio (upper CL):   0.9324 (comparable variabilities of T and R)
#   Confidence interval: 107.17% ... 124.97%  pass
#   Point estimate     : 115.73%              pass
#   Mixed (CI &amp; PE)    :                      pass
#
# Internal reference dataset 01 used and results to R's temporary
# folder. Additional outlier-analyis and box plot saved as PNG.
method.B(ola = TRUE, plot.bxp = TRUE, data = rds01)
# Should give the same as above. Additionally:
#   Recalculation due to presence of 2 outliers (subj. 45|52)
#   CVwR (outl. excl.) :  32.16% (reference-scaling applicable)
#   swR  (recalc.)     :   0.31374
#   Expanded limits    :  78.79% ... 126.93% [100exp(±0.760·swR)]
#   swT / swR (recalc.):   1.0881 (similar variabilities of T and R)
#   sw-ratio (upper CL):   1.3282 (comparable variabilities of T and R)
#   Confidence interval: pass
#   Point estimate     : pass
#   Mixed (CI &amp; PE)    : pass
#
# Same dataset. Show information about outliers and the model-table.
method.B(ola = TRUE, print = FALSE, verbose = TRUE, data = rds01)
# data.frame of results (full precision) shown in the console.
x &lt;- method.B(ola = TRUE, print = FALSE, details = TRUE, data = rds01)
print(x, row.names = FALSE)
# Compare Method B with Method A for all reference datasets.

ds &lt;- substr(grep("rds", unname(unlist(data(package = "replicateBE"))),
                  value = TRUE), start = 1, stop = 5)
for (i in seq_along(ds)) {
  A &lt;- method.A(print=FALSE, details=TRUE, data=eval(parse(text=ds[i])))$BE
  B &lt;- method.B(print=FALSE, details=TRUE, data=eval(parse(text=ds[i])))$BE
  r &lt;- paste0("A ", A, ", B ", B, " - ")
  cat(paste0(ds[i], ":"), r)
  if (A == B) {
    cat("Methods A and B agree.\n")
  } else {
    if (A == "fail" &amp; B == "pass") {
      cat("Method A is conservative.\n")
    } else {
      cat("Method B is conservative.\n")
    }
  }
}
# should give
#   rds01: A pass, B pass - Methods A and B agree.
#   ...
#   rds14: A pass, B fail - Method B is conservative.
#   ...

# Health Canada: Only the PE of Cmax has to lie within 80.0-125.0%
# (i.e., no CI is required). With alpha = 0.5 the CI is practically
# supressed (zero width) and ignored in the assessment.
x    &lt;- method.B(alpha = 0.5, regulator = "HC", option = 1,
                 data = rds03, print = FALSE, details = TRUE)[19:20]
x[1] &lt;- round(x[1], 1) # only one decimal place for HC
print(x, row.names = FALSE)
# Should result in:
# PE(%)  GMR
# 124.5 pass
</code></pre>

<hr>
<h2 id='refdata'>
Reference Datasets
</h2><span id='topic+data'></span>

<h3>Description</h3>

<p>Datasets of replicate designs from the public domain, edited, or obtained by simulations to be evaluated by <code>method.A()</code>, <code>method.B()</code>, or <code>ABE()</code>.
</p>


<h3>Details</h3>


<table>
<tr>
 <td style="text-align: left;">
  Design </td><td style="text-align: left;"> Specification </td><td style="text-align: center;"> Dataset </td><td style="text-align: right;"> N </td><td style="text-align: center;"> CV<sub>wR</sub> (%) </td><td style="text-align: left;"> Evaluation</td>
</tr>
<tr>
 <td style="text-align: left;">
  TRTR|RTRT </td><td style="text-align: left;"> full </td><td style="text-align: center;"> <code>rds01</code> </td><td style="text-align: right;"> 77 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRTR|RTRT </td><td style="text-align: left;"> full </td><td style="text-align: center;"> <code>rds06</code> </td><td style="text-align: right;"> 77 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRTR|RTRT </td><td style="text-align: left;"> full </td><td style="text-align: center;"> <code>rds12</code> </td><td style="text-align: right;"> 77 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRTR|RTRT </td><td style="text-align: left;"> full </td><td style="text-align: center;"> <code>rds14</code> </td><td style="text-align: right;"> 77 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRTR|RTRT </td><td style="text-align: left;"> full </td><td style="text-align: center;"> <code>rds18</code> </td><td style="text-align: right;"> 77 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRTR|RTRT </td><td style="text-align: left;"> full </td><td style="text-align: center;"> <code>rds21</code> </td><td style="text-align: right;"> 77 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRTR|RTRT </td><td style="text-align: left;"> full </td><td style="text-align: center;"> <code>rds19</code> </td><td style="text-align: right;"> 61 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRTR|RTRT </td><td style="text-align: left;"> full </td><td style="text-align: center;"> <code>rds20</code> </td><td style="text-align: right;"> 61 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRTR|RTRT </td><td style="text-align: left;"> full </td><td style="text-align: center;"> <code>rds08</code> </td><td style="text-align: right;"> 222 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRTR|RTRT </td><td style="text-align: left;"> full </td><td style="text-align: center;"> <code>rds09</code> </td><td style="text-align: right;"> 222 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRTR|RTRT </td><td style="text-align: left;"> full </td><td style="text-align: center;"> <code>rds13</code> </td><td style="text-align: right;"> 222 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRTR|RTRT </td><td style="text-align: left;"> full </td><td style="text-align: center;"> <code>rds15</code> </td><td style="text-align: right;"> 222 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRTR|RTRT </td><td style="text-align: left;"> full </td><td style="text-align: center;"> <code>rds25</code> </td><td style="text-align: right;"> 70 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRTR|RTRT </td><td style="text-align: left;"> full </td><td style="text-align: center;"> <code>rds29</code> </td><td style="text-align: right;"> 12 </td><td style="text-align: center;"> &lt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code>, <code>ABE()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRRT|RTTR </td><td style="text-align: left;"> full </td><td style="text-align: center;"> <code>rds26</code> </td><td style="text-align: right;"> 54 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRRT|RTTR </td><td style="text-align: left;"> full </td><td style="text-align: center;"> <code>rds05</code> </td><td style="text-align: right;"> 26 </td><td style="text-align: center;"> &lt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code>, <code>ABE()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRRT|RTTR </td><td style="text-align: left;"> full </td><td style="text-align: center;"> <code>rds11</code> </td><td style="text-align: right;"> 37 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRRT|RTTR </td><td style="text-align: left;"> full </td><td style="text-align: center;"> <code>rds16</code> </td><td style="text-align: right;"> 38 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TTRR|RRTT </td><td style="text-align: left;"> full </td><td style="text-align: center;"> <code>rds28</code> </td><td style="text-align: right;"> 64 </td><td style="text-align: center;"> &lt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code>, <code>ABE()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRTR|RTRT|TRRT|RTTR </td><td style="text-align: left;"> full </td><td style="text-align: center;"> <code>rds23</code> </td><td style="text-align: right;"> 22 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRRT|RTTR|TTRR|RRTT </td><td style="text-align: left;"> full </td><td style="text-align: center;"> <code>rds24</code> </td><td style="text-align: right;"> 39 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRT|RTR </td><td style="text-align: left;"> full </td><td style="text-align: center;"> <code>rds03</code> </td><td style="text-align: right;"> 77 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRT|RTR </td><td style="text-align: left;"> full </td><td style="text-align: center;"> <code>rds17</code> </td><td style="text-align: right;"> 19 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRR|RTT </td><td style="text-align: left;"> full </td><td style="text-align: center;"> <code>rds10</code> </td><td style="text-align: right;"> 18 </td><td style="text-align: center;"> &lt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code>, <code>ABE()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TR|RT|TT|RR </td><td style="text-align: left;"> Balaam’s </td><td style="text-align: center;"> <code>rds27</code> </td><td style="text-align: right;"> 312 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRR|RTR|RRT </td><td style="text-align: left;"> partial </td><td style="text-align: center;"> <code>rds02</code> </td><td style="text-align: right;"> 24 </td><td style="text-align: center;"> &lt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code>, <code>ABE()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRR|RTR|RRT </td><td style="text-align: left;"> partial </td><td style="text-align: center;"> <code>rds04</code> </td><td style="text-align: right;"> 51 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRR|RTR|RRT </td><td style="text-align: left;"> partial </td><td style="text-align: center;"> <code>rds07</code> </td><td style="text-align: right;"> 360 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRR|RTR|RRT </td><td style="text-align: left;"> partial </td><td style="text-align: center;"> <code>rds30</code> </td><td style="text-align: right;"> 14 </td><td style="text-align: center;"> &lt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code>, <code>ABE()</code></td>
</tr>
<tr>
 <td style="text-align: left;">
  TRR|RTR </td><td style="text-align: left;"> partial </td><td style="text-align: center;"> <code>rds22</code> </td><td style="text-align: right;"> 36 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code>
  </td>
</tr>

</table>

<p>In full replicate designs <em>both</em> R and T are administered twice (in 3-period designs to ½ of the subjects).<br />
Balaam’s design is a mixture of a conventional crossover (½ of the subjects) and a replicate design (¼ of the subjects receive <em>either</em> R <em>or</em> T twice).<br />
In partial replicate designs <em>only</em> R is administered twice.
</p>


<h3>Author(s)</h3>

<p>Helmut Schütz (R-code for simulations by Detlew Labes), Michael Tomashevskiy (simulations in Phoenix NLME)
</p>


<h3>Source</h3>


<table>
<tr>
 <td style="text-align: center;">
    Dataset </td><td style="text-align: left;"> Origin </td><td style="text-align: left;"> Description</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds01</code> </td><td style="text-align: left;"> EMA </td><td style="text-align: left;"> Data set in Annex II</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds06</code> </td><td style="text-align: left;"> <code>rds01</code> edited </td><td style="text-align: left;"> T and R switched</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds12</code> </td><td style="text-align: left;"> Phoenix NLME </td><td style="text-align: left;"> Simulated with extreme variability</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds14</code> </td><td style="text-align: left;"> Phoenix NLME </td><td style="text-align: left;"> Simulated with high variability and number of dropouts increasing with period</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds18</code> </td><td style="text-align: left;"> <code>rds14</code> edited </td><td style="text-align: left;"> Removed T data of subjects 63–78</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds21</code> </td><td style="text-align: left;"> <code>rds01</code> edited </td><td style="text-align: left;"> One extreme result of subjects 45 &amp; 52 set to NA</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds19</code> </td><td style="text-align: left;"> <code>rds18</code> edited </td><td style="text-align: left;"> Removed data of subjects 63–78</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds20</code> </td><td style="text-align: left;"> <code>rds19</code> edited </td><td style="text-align: left;"> Outlier of R (subject 1) introduced: original value ×100</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds08</code> </td><td style="text-align: left;"> R </td><td style="text-align: left;"> Simulated with slight heteroscedasticity</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds09</code> </td><td style="text-align: left;"> <code>rds08</code> </td><td style="text-align: left;"> Wide numeric range (data of last 37 subjects multiplied by 1,000,000)</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds13</code> </td><td style="text-align: left;"> <code>rds08</code> edited </td><td style="text-align: left;"> Highly incomplete (approx. 50% of period 4 data deleted)</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds15</code> </td><td style="text-align: left;"> <code>rds08</code> edited </td><td style="text-align: left;"> Highly incomplete (approx. 50% of period 4 data coded as missing <code>'NA'</code>)</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds25</code> </td><td style="text-align: left;"> R </td><td style="text-align: left;"> Simulated with heteroscedasticity</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds29</code> </td><td style="text-align: left;"> R </td><td style="text-align: left;"> Simulated with heteroscedasticity; imbalanced and incomplete</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds26</code> </td><td style="text-align: left;"> Patterson &amp; Jones 2016 </td><td style="text-align: left;"> C<sub>max</sub> data given in Tables 4.30 &amp; 4.31</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds05</code> </td><td style="text-align: left;"> Shumaker &amp; Metzler </td><td style="text-align: left;"> C<sub>max</sub> data given in the Appendix</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds11</code> </td><td style="text-align: left;"> Hauschke <em>et al.</em> </td><td style="text-align: left;"> C<sub>max</sub> data given in Table 9.6.</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds16</code> </td><td style="text-align: left;"> FDA, CDER </td><td style="text-align: left;"> C<sub>max</sub> data of Drug 14a</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds28</code> </td><td style="text-align: left;"> R </td><td style="text-align: left;"> Simulated with homoscedasticity</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds23</code> </td><td style="text-align: left;"> FDA, CDER </td><td style="text-align: left;"> C<sub>max</sub> data of Drug </td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds24</code> </td><td style="text-align: left;"> FDA, CDER </td><td style="text-align: left;"> C<sub>max</sub> data of Drug 1</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds03</code> </td><td style="text-align: left;"> <code>rds01</code> edited </td><td style="text-align: left;"> Period 4 removed</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds17</code> </td><td style="text-align: left;"> <code>rds03</code> edited </td><td style="text-align: left;"> Highly unbalanced (twelve subjects in RTR and seven in TRT)</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds10</code> </td><td style="text-align: left;"> Chow &amp; Liu </td><td style="text-align: left;"> AUC data given in Table 9.3.3.</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds27</code> </td><td style="text-align: left;"> R </td><td style="text-align: left;"> Simulated with homoscedasticity</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds02</code> </td><td style="text-align: left;"> EMA </td><td style="text-align: left;"> Data set in Annex III</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds04</code> </td><td style="text-align: left;"> Patterson &amp; Jones 2012 </td><td style="text-align: left;"> C<sub>max</sub> data of Table II</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds07</code> </td><td style="text-align: left;"> R </td><td style="text-align: left;"> Simulated with homoscedasticity</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds30</code> </td><td style="text-align: left;"> R </td><td style="text-align: left;"> Simulated with heteroscedasticity; imbalanced and incomplete</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds22</code> </td><td style="text-align: left;"> R </td><td style="text-align: left;"> Simulated with homoscedasticity
  </td>
</tr>

</table>



<h3>References</h3>

<p>European Medicines Agency. London, 21 September 2016. <a href="https://www.ema.europa.eu/en/documents/other/31-annex-ii-statistical-analysis-bioequivalence-study-example-data-set_en.pdf"><em>Annex II</em></a>, <a href="https://www.ema.europa.eu/en/documents/other/statistical-method-equivalence-studies-annex-iii_en.pdf"><em>Annex III</em></a>.
</p>
<p>Patterson SD, Jones B. <em>Viewpoint: observations on scaled average bioequivalence.</em> Pharm Stat. 2012; 11(1): 1&ndash;7. <a href="https://doi.org/10.1002/pst.498">doi:10.1002/pst.498</a>
</p>
<p>Shumaker RC, Metzler CM. <em>The Phenytoin Trial is a Case Study of &lsquo;Individual&rsquo; Bioequivalence.</em> Drug Inf J. 1998; 32(4): 1063&ndash;72. <a href="https://doi.org/10.1177/009286159803200426">doi:10.1177/009286159803200426</a>
</p>
<p>Chow SC, Liu JP. <em>Design and Analysis of Bioavailability and Bioequivalence Studies.</em> Boca Raton: CRC Press; 3<sup>rd</sup> edition 2009. p275.
</p>
<p>Hauschke D, Steinijans VW, Pigeot I. <em>Bioequivalence Studies in Drug Development.</em> Chichester: John Wiley; 2007. p216.
</p>
<p>Patterson SD, Jones B. <em>Bioequivalence and Statistics in Clinical Pharmacology.</em> Boca Raton: CRC Press; 2<sup>nd</sup> edition 2016. p105&ndash;6.
</p>
<p><abbr><span class="acronym">U.S.</span></abbr> Food and Drug Administration, Center for Drug Evaluation and Research. <em>Bioequivalence Studies.</em> Rockville, 1997. <a href="https://web.archive.org/web/20170723175533/https://www.fda.gov/downloads/Drugs/ScienceResearch/UCM301481.zip">bioequivalence study files</a> (archived 2017-07-23)
</p>


<h3>See Also</h3>

<p>4-period full replicates<br />
<a href="#topic+TRTR.RTRT">TRTR.RTRT</a>, <a href="#topic+TRRT.RTTR">TRRT.RTTR</a>, <a href="#topic+TTRR.RRTT">TTRR.RRTT</a>, <a href="#topic+TRTR.RTRT.TRRT.RTTR">TRTR.RTRT.TRRT.RTTR</a>, <a href="#topic+TRRT.RTTR.TTRR.RRTT">TRRT.RTTR.TTRR.RRTT</a><br />
2-period replicate (Balaam’s design)<br />
<a href="#topic+TR.RT.TT.RR">TR.RT.TT.RR</a><br />
3-period full replicates<br />
<a href="#topic+TRT.RTR">TRT.RTR</a>, <a href="#topic+TRR.RTT">TRR.RTT</a><br />
3-period partial replicates<br />
<a href="#topic+TRR.RTR.RRT">TRR.RTR.RRT</a>, <a href="#topic+TRR.RTR">TRR.RTR</a>
</p>


<h3>Examples</h3>

<pre><code class='language-R'># show structure of all data sets
ds &lt;- substr(grep("rds", unname(unlist(data(package = "replicateBE"))),
                  value = TRUE), start = 1, stop = 5)
for (i in seq_along(ds)) {
  cat(ds[i], "\n")
  str(eval(parse(text = ds[i])))
}
</code></pre>

<hr>
<h2 id='TR.RT.TT.RR'>
Reference Dataset for TR|RT|TT|RR Replicate Designs
</h2><span id='topic+TR.RT.TT.RR'></span><span id='topic+rds27'></span>

<h3>Description</h3>

<p>Dataset for Balaam’s design obtained by simulations to be evaluated by <code>method.A()</code>, <code>method.B()</code>.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>rds27</code></pre>


<h3>Format</h3>


<ul>
<li><p> Reference Dataset 27 (<code>rds27</code>)<br />
312 subjects. Balanced (78 subjects in each of the four sequences) and incomplete (T of subject 111 missing in period 2 of sequence RT). No outliers.<br />
A data frame with 624 observations on the following 5 variables:
</p>

<dl>
<dt>rds27</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
            <code>subject</code> </td><td style="text-align: left;"> a factor with 312 levels: 1, 2, ..., 18</td>
</tr>
<tr>
 <td style="text-align: left;">
            <code>period</code> </td><td style="text-align: left;"> a factor with 2 levels: 1, 2</td>
</tr>
<tr>
 <td style="text-align: left;">
            <code>sequence</code> </td><td style="text-align: left;"> a factor with 4 levels: TR, RT, TT, RR</td>
</tr>
<tr>
 <td style="text-align: left;">
            <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
            <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses acceptable for reference-scaling (generally C<sub>max</sub>)
          </td>
</tr>

</table>

</dd>
</dl>

</li></ul>



<h3>Details</h3>


<table>
<tr>
 <td style="text-align: center;">
  Dataset </td><td style="text-align: right;"> N </td><td style="text-align: center;"> CV<sub>wR</sub> (%) </td><td style="text-align: left;"> Evaluation</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds27</code> </td><td style="text-align: right;"> 312 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>

</table>



<h3>Note</h3>

<p>In software sequences and treatments are ranked in lexical order. Hence, executing <code>str()</code> or <code>summary()</code> will show <code>sequence</code> as <code>"RR", "RT", "TR", "TT"</code> and <code>treatment</code> as <code>"R", "T"</code>. In <abbr><span class="acronym">BE</span></abbr> &ndash; by convention &ndash; sequences are ordered with <code>T</code> first. The package follows this convention.
</p>


<h3>Author(s)</h3>

<p>Helmut Schütz (R-code for simulations by Detlew Labes)
</p>


<h3>Source</h3>


<table>
<tr>
 <td style="text-align: center;">
    Dataset </td><td style="text-align: left;"> Origin </td><td style="text-align: left;"> Description</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds27</code> </td><td style="text-align: left;"> R </td><td style="text-align: left;"> Simulated with CV<sub>wT</sub> = CV<sub>wR</sub> = 35%, CV<sub>bT</sub> = CV<sub>bR</sub> = 75%, GMR 0.90.
  </td>
</tr>

</table>



<h3>Examples</h3>

<pre><code class='language-R'>str(rds27)
row &lt;- c(1:2, 157:158, 313:314, 469:470)
rds27[row, ]
summary(rds27[2:5])
</code></pre>

<hr>
<h2 id='TRR.RTR'>
Reference Dataset for TRR|RTR (extra-reference) Designs
</h2><span id='topic+TRR.RTR'></span><span id='topic+rds22'></span>

<h3>Description</h3>

<p>Dataset simulated to be evaluated by <code>method.A()</code>, <code>method.B()</code>.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>rds22</code></pre>


<h3>Format</h3>


<ul>
<li><p> Reference dataset 22<br />
Simulated with CV<sub>wT</sub> = CV<sub>wR</sub> = 45%, CV<sub>bT</sub> = CV<sub>bR</sub> = 100% GMR 0.90. 42 subjects.<br />
Balanced (21 subjects in each of the sequences) and complete (no missing data). No outliers.<br />
A data frame with 126 observations on the following 5 variables:
</p>

<dl>
<dt>rds22</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
        <code>subject</code> </td><td style="text-align: left;"> a factor with 42 levels: 1, 2, ..., 42</td>
</tr>
<tr>
 <td style="text-align: left;">
        <code>period</code> </td><td style="text-align: left;"> a factor with 3 levels: 1, 2, 3</td>
</tr>
<tr>
 <td style="text-align: left;">
        <code>sequence</code> </td><td style="text-align: left;"> a factor with 2 levels: TRR, RTR</td>
</tr>
<tr>
 <td style="text-align: left;">
        <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
        <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses acceptable for reference-scaling (generally C<sub>max</sub>)</td>
</tr>
<tr>
 <td style="text-align: left;">
        <code>logPK</code> </td><td style="text-align: left;"> a numeric vector of the natural logarithms of <code>PK</code>
        </td>
</tr>

</table>

</dd>
</dl>

</li></ul>



<h3>Details</h3>


<table>
<tr>
 <td style="text-align: center;">
  Dataset </td><td style="text-align: right;"> N </td><td style="text-align: center;"> C<sub>wR</sub> (%) </td><td style="text-align: left;"> Evaluation</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds22</code> </td><td style="text-align: right;"> 42 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code>
  </td>
</tr>

</table>



<h3>Note</h3>

<p>In software sequences and treatments are ranked in lexical order. Hence, executing <code>str()</code> or <code>summary()</code> will show <code>sequence</code> as <code>"RTR", "TRR"</code> and <code>treatment</code> as <code>"R", "T"</code>. In <abbr><span class="acronym">BE</span></abbr> &ndash; by convention &ndash; sequences are ordered with <code>T</code> first. The package follows this convention.<br />
This partial replicate design is also known as the &lsquo;extra-reference design&rsquo;. Since the Test is not administered in all periods, lacking period effects must be assumed. In the presence of <em>true</em> period effects the treatment comparison will be biased. Hence, this design is not recommended.
</p>


<h3>Author(s)</h3>

<p>Helmut Schütz (R-code for simulations by Detlew Labes)
</p>


<h3>Source</h3>


<table>
<tr>
 <td style="text-align: center;">
  Dataset </td><td style="text-align: left;"> Origin </td><td style="text-align: left;"> Description</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds22</code> </td><td style="text-align: left;"> R </td><td style="text-align: left;"> Simulated with homoscedasticity.
  </td>
</tr>

</table>



<h3>Examples</h3>

<pre><code class='language-R'>str(rds22)
rds22[61:66, ]
summary(rds22[2:5])
</code></pre>

<hr>
<h2 id='TRR.RTR.RRT'>
Reference Datasets for TRR|RTR|RRT (partial) Replicate Designs
</h2><span id='topic+TRR.RTR.RRT'></span><span id='topic+rds02'></span><span id='topic+rds04'></span><span id='topic+rds07'></span><span id='topic+rds30'></span>

<h3>Description</h3>

<p>Datasets from the public domain or simulated to be evaluated by <code>method.A()</code>, <code>method.B()</code>, or <code>ABE()</code>.
</p>


<h3>Format</h3>


<ul>
<li><p> Reference Dataset 02<br />
24 subjects.<br />
Balanced (eight subjects in each of the three sequences) and complete (no missing data). No outliers.<br />
A data frame with 72 observations on the following 6 variables:
</p>

<dl>
<dt>rds02</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
              <code>subject</code> </td><td style="text-align: left;"> a factor with 24 levels: 1, 2, ..., 24</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>period</code> </td><td style="text-align: left;"> a factor with 3 levels: 1, 2, 3</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>sequence</code> </td><td style="text-align: left;"> a factor with 3 levels: TRR, RTR, RRT</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses acceptable for reference-scaling (generally C<sub>max</sub>)</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>logPK</code> </td><td style="text-align: left;"> a numeric vector of the natural logarithms of <code>PK</code>
            </td>
</tr>

</table>

</dd>
</dl>
<p>In the source evaluated by <abbr><span class="acronym">SAS</span></abbr> v9.1 for <abbr><span class="acronym">ABEL</span></abbr>. Reported results:
</p>
<dl>
<dt>SAS Proc GLM</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
              <code>CVwR</code> </td><td style="text-align: left;"> 11.2%</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>PE</code> </td><td style="text-align: left;"> 102.26% (Method A and B)</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>90% CI</code> </td><td style="text-align: left;"> 97.32% – 107.46% (Method A and B)
            </td>
</tr>

</table>

</dd>
</dl>

</li>
<li><p> Reference Dataset 04<br />
Data set of Table II given by Patterson &amp; Jones. 51 subjects.<br />
Balanced (17 subjects in each of the three sequences) and complete. No outliers.<br />
A data frame with 153 observations on the following 5 variables:
</p>

<dl>
<dt>rds04</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
              <code>subject</code> </td><td style="text-align: left;"> a factor with 51 levels: 1, 2, ..., 56</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>period</code> </td><td style="text-align: left;"> a factor with 3 levels: 1, 2, 3</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>sequence</code> </td><td style="text-align: left;"> a factor with 3 levels: TRR, RTR, RRT</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses (here C<sub>max</sub>)
            </td>
</tr>

</table>

</dd>
</dl>
<p>In the source evaluated by <abbr><span class="acronym">SAS</span></abbr> with the <abbr><span class="acronym">FDA</span></abbr>’s mixed effects model (termed &lsquo;Method C&rsquo; by the <abbr><span class="acronym">EMA</span></abbr>; not compatible with the guideline). Reported results:
</p>
<dl>
<dt>SAS Proc MIXED</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
              <code>CVwR</code> </td><td style="text-align: left;"> 61%</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>PE</code> </td><td style="text-align: left;"> 137%</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>90% CI</code> </td><td style="text-align: left;"> 119% – 159%
            </td>
</tr>

</table>

</dd>
</dl>

</li>
<li><p> Reference Dataset 07<br />
Simulated with CV<sub>wT</sub> = CV<sub>wR</sub> = 35%, GMR 0.90. 360 subjects.<br />
Balanced (120 subjects in each of the three sequences) and complete. No outliers.<br />
A data frame with 1,080 observations on the following 5 variables:
</p>

<dl>
<dt>rds07</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
              <code>subject</code> </td><td style="text-align: left;"> a factor with 360 levels: 1, 2, ..., 360</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>period</code> </td><td style="text-align: left;"> a factor with 3 levels: 1, 2, 3</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>sequence</code> </td><td style="text-align: left;"> a factor with 3 levels: TRR, RTR, RRT</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses (generally C<sub>max</sub>)
            </td>
</tr>

</table>

</dd>
</dl>

</li>
<li><p> Reference Dataset 30<br />
Simulated with heteroscedasticity (CV<sub>wT</sub> = 14%, CV<sub>wR</sub> = 28%, CV<sub>bT</sub> = 28%, CV<sub>bR</sub> = 56%), GMR = 0.90. 12 subjects. 14 subjects.<br />
Imbalanced (six subjects in sequence TRR, five in RTR, and three RRT) and incomplete (two missings in sequences TRR and RTR and three in sequence RRT). Missings / period: 0/1, 0/2, 7/3. No outliers.<br />
A data frame with 35 observations on the following 5 variables:
</p>

<dl>
<dt>rds30</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
              <code>subject</code> </td><td style="text-align: left;"> a factor with 14 levels: 1, 2, ..., 39</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>period</code> </td><td style="text-align: left;"> a factor with 3 levels: 1, 2, 3</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>sequence</code> </td><td style="text-align: left;"> a factor with 3 levels: TRR, RTR, RRT</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses (generally C<sub>max</sub>)
            </td>
</tr>

</table>

</dd>
</dl>

</li></ul>



<h3>Details</h3>


<table>
<tr>
 <td style="text-align: center;">
      Dataset </td><td style="text-align: right;"> N </td><td style="text-align: center;"> CV<sub>wR</sub> (%) </td><td style="text-align: left;"> Evaluation</td>
</tr>
<tr>
 <td style="text-align: center;">
      <code>rds02</code> </td><td style="text-align: right;"> 24 </td><td style="text-align: center;"> &lt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code>, <code>ABE()</code></td>
</tr>
<tr>
 <td style="text-align: center;">
      <code>rds04</code> </td><td style="text-align: right;"> 51 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: center;">
      <code>rds07</code> </td><td style="text-align: right;"> 360 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: center;">
      <code>rds30</code> </td><td style="text-align: right;"> 14 </td><td style="text-align: center;"> &lt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code>, <code>ABE()</code>
  </td>
</tr>

</table>



<h3>Note</h3>

<p>In software sequences and treatments are ranked in lexical order. Hence, executing <code>str()</code> or <code>summary()</code> will show <code>sequence</code> as <code>"RRT", "RTR", "TRR"</code> and <code>treatment</code> as <code>"R", "T"</code>. In <abbr><span class="acronym">BE</span></abbr> &ndash; by convention &ndash; sequences are ordered with <code>T</code> first. The package follows this convention.
</p>


<h3>Author(s)</h3>

<p>Helmut Schütz (R-code for simulations by Detlew Labes)
</p>


<h3>Source</h3>


<table>
<tr>
 <td style="text-align: center;">
    Dataset </td><td style="text-align: left;"> Origin </td><td style="text-align: left;"> Description</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds02</code> </td><td style="text-align: left;"> EMA </td><td style="text-align: left;"> Annex III.</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds04</code> </td><td style="text-align: left;"> Patterson &amp; Jones </td><td style="text-align: left;"> C<sub>max</sub> data of Table II.</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds07</code> </td><td style="text-align: left;"> R </td><td style="text-align: left;"> Large simulated data set with homoscedasticity.</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds30</code> </td><td style="text-align: left;"> R </td><td style="text-align: left;"> Simulated with heteroscedasticity; imbalanced and incomplete.
  </td>
</tr>

</table>



<h3>References</h3>

<p>European Medicines Agency. London, 21 September 2016. <a href="https://www.ema.europa.eu/en/documents/other/31-annex-i-statistical-analysis-methods-compatible-ema-bioequivalence-guideline_en.pdf"><em>Annex I</em></a>, <a href="https://www.ema.europa.eu/en/documents/other/statistical-method-equivalence-studies-annex-iii_en.pdf"><em>Annex III</em></a>.
</p>
<p>Patterson SD, Jones B. <em>Viewpoint: observations on scaled average bioequivalence.</em> Pharm Stat. 2012; 11(1): 1&ndash;7. <a href="https://doi.org/10.1002/pst.498">doi:10.1002/pst.498</a>
</p>


<h3>Examples</h3>

<pre><code class='language-R'>str(rds02)
row &lt;- c(10:12, 1:3, 16:18)
rds02[row, ]
summary(rds02[2:6])
</code></pre>

<hr>
<h2 id='TRR.RTT'>
Reference Dataset for TRR|RTT Replicate Designs
</h2><span id='topic+TRR.RTT'></span><span id='topic+rds10'></span>

<h3>Description</h3>

<p>Dataset from the public domain to be evaluated by <code>method.A()</code>, <code>method.B()</code>, or <code>ABE()</code>.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>rds10</code></pre>


<h3>Format</h3>


<ul>
<li><p> Reference Dataset 10<br />
18 subjects.<br />
Balanced (nine subjects in both sequences) and complete. No outliers.<br />
A data frame with 54 observations on the following 5 variables:
</p>

<dl>
<dt>rds10</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
        <code>subject</code> </td><td style="text-align: left;"> a factor with 18 levels: 1, 2, ..., 18</td>
</tr>
<tr>
 <td style="text-align: left;">
        <code>period</code> </td><td style="text-align: left;"> a factor with 3 levels: 1, 2, 3</td>
</tr>
<tr>
 <td style="text-align: left;">
        <code>sequence</code> </td><td style="text-align: left;"> a factor with 2 levels: TRR, RTT</td>
</tr>
<tr>
 <td style="text-align: left;">
        <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
        <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses (here AUC)
        </td>
</tr>

</table>

</dd>
</dl>

</li></ul>



<h3>Details</h3>


<table>
<tr>
 <td style="text-align: center;">
  Dataset </td><td style="text-align: right;"> N </td><td style="text-align: center;"> CV<sub>wR</sub> (%) </td><td style="text-align: left;"> Evaluation</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds10</code> </td><td style="text-align: right;"> 36 </td><td style="text-align: center;"> &lt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code>, <code>ABE()</code>
  </td>
</tr>

</table>



<h3>Note</h3>

<p>In software sequences and treatments are ranked in lexical order. Hence, executing <code>str()</code> or <code>summary()</code> will show <code>sequence</code> as <code>"RTT", "TRR"</code> and <code>treatment</code> as <code>"R", "T"</code>. In <abbr><span class="acronym">BE</span></abbr> &ndash; by convention &ndash; sequences are ordered with <code>T</code> first. The package follows this convention.<br />
In analogy to the <abbr><span class="acronym">EMA</span></abbr>’s Q&amp;A: Uncertain estimate of <code>CVwR</code> since less than twelve subjects in sequence TRR.
</p>


<h3>Source</h3>


<table>
<tr>
 <td style="text-align: center;">
  Dataset </td><td style="text-align: left;"> Origin </td><td style="text-align: left;"> Description</td>
</tr>
<tr>
 <td style="text-align: center;">
  <code>rds10</code> </td><td style="text-align: left;"> Chow &amp; Liu </td><td style="text-align: left;"> AUC data given in Table 9.3.3.
  </td>
</tr>

</table>



<h3>References</h3>

<p>Chow SC, Liu JP. <em>Design and Analysis of Bioavailability and Bioequivalence Studies.</em> Boca Raton: CRC Press; 3<sup>rd</sup> edition 2009. p275.
</p>


<h3>Examples</h3>

<pre><code class='language-R'>str(rds10)
row &lt;- c(1:3, 28:30)
rds10[row, ]
summary(rds10[2:5])
</code></pre>

<hr>
<h2 id='TRRT.RTTR'>
Reference Datasets for TRRT|RTTR Replicate Designs
</h2><span id='topic+TRRT.RTTR'></span><span id='topic+rds05'></span><span id='topic+rds11'></span><span id='topic+rds16'></span>

<h3>Description</h3>

<p>Datasets from the public domain to be evaluated by <code>method.A()</code>, <code>method.B()</code>, or <code>ABE()</code>.
</p>


<h3>Format</h3>


<ul>
<li><p> Reference Dataset 05<br />
26 subjects.<br />
Balanced (13 subjects in both sequences) and complete. No outliers.<br />
A data frame with 104 observations on the following 5 variables:
</p>

<dl>
<dt>rds05</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
              <code>subject</code> </td><td style="text-align: left;"> a factor with 26 levels: 1, 2, ..., 26</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>period</code> </td><td style="text-align: left;"> a factor with 4 levels: 1, 2, 3, 4</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>sequence</code> </td><td style="text-align: left;"> a factor with 2 levels: TRRT, RTTR</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses (here C<sub>max</sub>)
            </td>
</tr>

</table>

</dd>
</dl>
<p>In the source evaluated by <abbr><span class="acronym">SAS</span></abbr> with the <abbr><span class="acronym">FDA</span></abbr>’s mixed effects model (termed &lsquo;Method C&rsquo; by the <abbr><span class="acronym">EMA</span></abbr>; not compatible with the guideline). Reported results:
</p>
<dl>
<dt>SAS Proc Mixed</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
              <code>CVwR</code> </td><td style="text-align: left;"> 5.47%</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>CVwT</code> </td><td style="text-align: left;"> 6.75%</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>PE</code> </td><td style="text-align: left;"> 107.90%</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>90% CI</code> </td><td style="text-align: left;"> 103.66% – 112.2%
            </td>
</tr>

</table>

</dd>
</dl>

</li>
<li><p> Reference Dataset 11<br />
37 subjects.<br />
Unbalanced (18 subjects in sequence TRRT and 19 subjects in RTTR) and complete. No outliers.<br />
A data frame with 148 observations on the following 5 variables
</p>

<dl>
<dt>rds11</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
              <code>subject</code> </td><td style="text-align: left;"> a factor with 37 levels: 1, 2, ..., 37</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>period</code> </td><td style="text-align: left;"> a factor with 4 levels: 1, 2, 3, 4</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>sequence</code> </td><td style="text-align: left;"> a factor with 2 levels: TRRT, RTTR</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses (here C<sub>max</sub>)
            </td>
</tr>

</table>

</dd>
</dl>
<p>In the source evaluated by <abbr><span class="acronym">SAS</span></abbr> with the <abbr><span class="acronym">FDA</span></abbr>’s mixed effects model (termed &lsquo;Method C&rsquo; by the <abbr><span class="acronym">EMA</span></abbr>; not compatible with the guideline). Reported results:
</p>
<dl>
<dt>SAS Proc MIXED</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
              <code>PE</code> </td><td style="text-align: left;"> 90.0%</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>90% CI</code> </td><td style="text-align: left;"> 79.6% – 101.7%
            </td>
</tr>

</table>

</dd>
</dl>

</li>
<li><p> Reference Dataset 16<br />
38 subjects.<br />
Unbalanced (18 subjects in sequence TRRT and 20 in RTTR) and complete. No outliers.<br />
A data frame with 152 observations on the following 5 variables:
</p>

<dl>
<dt>rds16</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
              <code>subject</code> </td><td style="text-align: left;"> a factor with 38 levels: 1, 2, ..., 38</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>period</code> </td><td style="text-align: left;"> a factor with 4 levels: 1, 2, 3, 4</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>sequence</code> </td><td style="text-align: left;"> a factor with 2 levels: TRRT, RTTR</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses (here C<sub>max</sub>)
            </td>
</tr>

</table>

</dd>
</dl>

</li></ul>



<h3>Details</h3>


<table>
<tr>
 <td style="text-align: center;">
    Dataset </td><td style="text-align: right;"> N </td><td style="text-align: center;"> CV<sub>wR</sub> (%) </td><td style="text-align: left;"> Evaluation</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds05</code> </td><td style="text-align: right;"> 26 </td><td style="text-align: center;"> &lt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code>, <code>ABE()</code></td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds11</code> </td><td style="text-align: right;"> 37 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds16</code> </td><td style="text-align: right;"> 38 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code>
  </td>
</tr>

</table>



<h3>Note</h3>

<p>In software sequences and treatments are ranked in lexical order. Hence, executing <code>str()</code> or <code>summary()</code> will show <code>sequence</code> as <code>"RTTR", "TRRT"</code> and <code>treatment</code> as <code>"R", "T"</code>. In <abbr><span class="acronym">BE</span></abbr> &ndash; by convention &ndash; sequences are ordered with <code>T</code> first. The package follows this convention.
</p>


<h3>Source</h3>


<table>
<tr>
 <td style="text-align: center;">
    Dataset </td><td style="text-align: left;"> Origin </td><td style="text-align: left;"> Description</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds05</code> </td><td style="text-align: left;"> Shumaker &amp; Metzler </td><td style="text-align: left;"> C<sub>max</sub> data given in the Appendix.</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds11</code> </td><td style="text-align: left;"> Hauschke <em>et al.</em> </td><td style="text-align: left;"> C<sub>max</sub> data given in Table 9.6.</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds16</code> </td><td style="text-align: left;"> FDA, CDER </td><td style="text-align: left;"> C<sub>max</sub> data of Drug 14a.
  </td>
</tr>

</table>



<h3>References</h3>

<p>Shumaker RC, Metzler CM. <em>The Phenytoin Trial is a Case Study of &lsquo;Individual&rsquo; Bioequivalence.</em> Drug Inf J. 1998; 32(4): 1063&ndash;72. <a href="https://doi.org/10.1177/009286159803200426">doi:10.1177/009286159803200426</a>
</p>
<p>Hauschke D, Steinijans VW, Pigeot I. <em>Bioequivalence Studies in Drug Development.</em> Chichester: John Wiley; 2007. p216.
</p>
<p><abbr><span class="acronym">U.S.</span></abbr> Food and Drug Administration, Center for Drug Evaluation and Research. <em>Bioequivalence Studies.</em> Rockville, 1997. <a href="https://web.archive.org/web/20170723175533/https://www.fda.gov/downloads/Drugs/ScienceResearch/UCM301481.zip">bioequivalence study files</a> (archived 2017-07-23)
</p>


<h3>Examples</h3>

<pre><code class='language-R'>str(rds05)
summary(rds05[2:5])
head(rds11, 8)
</code></pre>

<hr>
<h2 id='TRRT.RTTR.TTRR.RRTT'>
Reference Dataset for TRRT|RTTR|TTRR|RRTT Designs
</h2><span id='topic+TRRT.RTTR.TTRR.RRTT'></span><span id='topic+rds24'></span>

<h3>Description</h3>

<p>Dataset from the public domain to be evaluated by <code>method.A()</code> and/or <code>method.B()</code>.
</p>


<h3>Format</h3>


<ul>
<li><p> Reference Dataset 24<br />
40 subjects (one completely missing).<br />
Unbalanced (nine subjects in sequence TRRT and ten in each of the other three) and complete. Two outliers (subject 3 in sequence RTTR and subject 30 in sequence TTRR).<br />
A data frame with 160 observations on the following 5 variables:
</p>

<dl>
<dt>rds24</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
          <code>subject</code> </td><td style="text-align: left;"> a factor with 40 levels: 1, 2, ..., 932</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>period</code> </td><td style="text-align: left;"> a factor with 4 levels: 1, 2, 3, 4</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>sequence</code> </td><td style="text-align: left;"> a factor with 4 levels: TRRT, RTTR, TTRR, RRTT</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses acceptable for reference-scaling (here C<sub>max</sub>)
          </td>
</tr>

</table>

</dd>
</dl>

</li></ul>



<h3>Details</h3>


<table>
<tr>
 <td style="text-align: center;">
    Dataset </td><td style="text-align: right;"> N </td><td style="text-align: center;"> CV<sub>wR</sub> (%) </td><td style="text-align: left;"> Evaluation</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds24</code> </td><td style="text-align: right;"> 39 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code>
  </td>
</tr>

</table>



<h3>Note</h3>

<p>In software sequences and treatments are ranked in lexical order. Hence, executing <code>str()</code> or <code>summary()</code> will show <code>sequence</code> as <code>"RRTT", "RTTR", "TRRT", "TTRR"</code> and <code>treatment</code> as <code>"R", "T"</code>. In <abbr><span class="acronym">BE</span></abbr> &ndash; by convention &ndash; sequences are ordered with <code>T</code> first. The package follows this convention.
</p>


<h3>Source</h3>


<table>
<tr>
 <td style="text-align: center;">
  Dataset </td><td style="text-align: left;"> Origin </td><td style="text-align: left;"> Description</td>
</tr>
<tr>
 <td style="text-align: center;">
  <code>rds24</code> </td><td style="text-align: left;"> FDA, CDER </td><td style="text-align: left;"> C<sub>max</sub> data of Drug 1.
  </td>
</tr>

</table>



<h3>References</h3>

<p><abbr><span class="acronym">U.S.</span></abbr> Food and Drug Administration, Center for Drug Evaluation and Research. <em>Bioequivalence Studies.</em> Rockville, 1997. <a href="https://web.archive.org/web/20170723175533/https://www.fda.gov/downloads/Drugs/ScienceResearch/UCM301481.zip">bioequivalence study files</a> (archived 2017-07-23)
</p>


<h3>Examples</h3>

<pre><code class='language-R'>str(rds24)
row &lt;- c(13:16, 9:12, 1:4, 5:8)
rds24[row, ]
summary(rds24[2:5])
</code></pre>

<hr>
<h2 id='TRT.RTR'>
Reference Datasets for TRT|RTR Replicate Designs
</h2><span id='topic+TRT.RTR'></span><span id='topic+rds03'></span><span id='topic+rds17'></span>

<h3>Description</h3>

<p>Datasets from the public domain and edited to be evaluated by <code>method.A()</code> and/or <code>method.B()</code>.
</p>


<h3>Format</h3>


<ul>
<li><p> Reference dataset 03<br />
Based on <code>rds01</code>. Removed all data of period 4. 77 subjects.<br />
Unbalanced (39 subjects in sequence TRT and 38 in RTR) and incomplete (six missings in sequence TRT and two in RTR). Missings / period: 0/1, 1/2, 7/3. Two outliers (subjects 45 and 52) in sequence RTR.<br />
A data frame with 223 observations on the following 6 variables:
</p>

<dl>
<dt>rds03</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
              <code>subject</code> </td><td style="text-align: left;"> a factor with 77 levels: 1, 2, ..., 78</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>period</code> </td><td style="text-align: left;"> a factor with 3 levels: 1, 2, 3</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>sequence</code> </td><td style="text-align: left;"> a factor with 2 levels: TRT, RTR</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses acceptable for reference-scaling (generally C<sub>max</sub>)
            </td>
</tr>

</table>

</dd>
</dl>

</li>
<li><p> Reference dataset 17<br />
Based on <code>rds03</code>. 19 subjects.<br />
Unbalanced (seven subjects in sequence TRT and twelve in RTR) and incomplete (one missing in sequence TRT). Missings / period: 0/1, 0/2, 1/3. One outlier (subject 18) in sequence RTR.<br />
A data frame with 56 observations on the following 6 variables:
</p>

<dl>
<dt>rds17</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
              <code>subject</code> </td><td style="text-align: left;"> a factor with 19 levels: 1, 2, ..., 22</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>period</code> </td><td style="text-align: left;"> a factor with 3 levels: 1, 2, 3</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>sequence</code> </td><td style="text-align: left;"> a factor with 2 levels: TRT, RTR</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
              <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses acceptable for reference-scaling (generally C<sub>max</sub>)
            </td>
</tr>

</table>

</dd>
</dl>

</li></ul>



<h3>Details</h3>


<table>
<tr>
 <td style="text-align: center;">
    Dataset </td><td style="text-align: right;"> N </td><td style="text-align: center;"> CV<sub>wR</sub> (%) </td><td style="text-align: left;"> Evaluation</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds03</code> </td><td style="text-align: right;"> 77 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds17</code> </td><td style="text-align: right;"> 19 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code>
  </td>
</tr>

</table>



<h3>Note</h3>

<p>In software sequences and treatments are ranked in lexical order. Hence, executing <code>str()</code> or <code>summary()</code> will show <code>sequence</code> as <code>"RTR", "TRT"</code> and <code>treatment</code> as <code>"R", "T"</code>. In <abbr><span class="acronym">BE</span></abbr> &ndash; by convention &ndash; sequences are ordered with <code>T</code> first. The package follows this convention.
</p>


<h3>Author(s)</h3>

<p>Helmut Schütz
</p>


<h3>Source</h3>


<table>
<tr>
 <td style="text-align: center;">
    Dataset </td><td style="text-align: left;"> Origin </td><td style="text-align: left;"> Description</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds03</code> </td><td style="text-align: left;"> <code>rds01</code> edited </td><td style="text-align: left;"> Period 4 removed.</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds17</code> </td><td style="text-align: left;"> <code>rds03</code> edited </td><td style="text-align: left;"> Highly unbalanced (seven subjects in TRT and twelve in RTR).
  </td>
</tr>

</table>



<h3>Examples</h3>

<pre><code class='language-R'>head(rds03, 6)
summary(rds03[2:5])
</code></pre>

<hr>
<h2 id='TRTR.RTRT'>
Reference Datasets for TRTR|RTRT Designs
</h2><span id='topic+TRTR.RTRT'></span><span id='topic+rds01'></span><span id='topic+rds06'></span><span id='topic+rds08'></span><span id='topic+rds09'></span><span id='topic+rds12'></span><span id='topic+rds13'></span><span id='topic+rds14'></span><span id='topic+rds15'></span><span id='topic+rds18'></span><span id='topic+rds19'></span><span id='topic+rds20'></span><span id='topic+rds21'></span><span id='topic+rds25'></span><span id='topic+rds26'></span><span id='topic+rds29'></span>

<h3>Description</h3>

<p>Datasets from the public domain, edited, or obtained by simulations to be evaluated by <code>method.A()</code> and/or <code>method.B()</code>.
</p>


<h3>Format</h3>


<ul>
<li><p> Reference dataset 01<br />
77 subjects.<br />
Unbalanced (39 subjects in sequence TRTR and 38 in RTRT) and incomplete (seven missings in sequence TRTR and three in sequence RTRT). Missings / period: 0/1, 1/2, 7/3, 2/4. Two outliers (subjects 45 and 52) in sequence RTRT.<br />
A data frame with 298 observations on the following 6 variables:
</p>

<dl>
<dt>rds01</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
          <code>subject</code> </td><td style="text-align: left;"> a factor with 77 levels: 1, 2, ..., 78</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>period</code> </td><td style="text-align: left;"> a factor with 4 levels: 1, 2, 3, 4</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>sequence</code> </td><td style="text-align: left;"> a factor with 2 levels: TRTR, RTRT</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses acceptable for reference-scaling (generally C<sub>max</sub>)</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>logPK</code> </td><td style="text-align: left;"> a numeric vector of the natural logarithms of <code>PK</code>
        </td>
</tr>

</table>

</dd>
</dl>
<p>In the source evaluated by <abbr><span class="acronym">SAS</span></abbr> v9.1 for <abbr><span class="acronym">ABEL</span></abbr>. Reported results:

</p>
<dl>
<dt>SAS Proc GLM</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
        <code>CVwR</code> </td><td style="text-align: left;"> 47.0%</td>
</tr>
<tr>
 <td style="text-align: left;">
        <code>PE</code> </td><td style="text-align: left;"> 115.66% (Method A)</td>
</tr>
<tr>
 <td style="text-align: left;"></td><td style="text-align: left;"> 115.73% (Method B)</td>
</tr>
<tr>
 <td style="text-align: left;">
        <code>90% CI</code> </td><td style="text-align: left;"> 107.11% – 124.89% (Method A)</td>
</tr>
<tr>
 <td style="text-align: left;"></td><td style="text-align: left;"> 107.17% – 124.97% (Method B)
      </td>
</tr>

</table>

</dd>
</dl>

</li>
<li><p> Reference dataset 06<br />
Based on <code>rds01</code>. 77 subjects. Responses of T and R switched.<br />
Unbalanced (39 subjects in sequence TRTR and 38 in RTRT) and incomplete (seven missings in sequence TRTR and three in sequence RTRT). Missings / period: 0/1, 1/2, 7/3, 2/4. No outliers.<br />
A data frame with 298 observations on the following 6 variables:
</p>

<dl>
<dt>rds06</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
          <code>subject</code> </td><td style="text-align: left;"> a factor with 77 levels: 1, 2, ..., 78</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>period</code> </td><td style="text-align: left;"> a factor with 4 levels: 1, 2, 3, 4</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>sequence</code> </td><td style="text-align: left;"> a factor with 2 levels: TRTR, RTRT</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses acceptable for reference-scaling (generally C<sub>max</sub>)
        </td>
</tr>

</table>

</dd>
</dl>

</li>
<li><p> Reference dataset 08<br />
Simulated with slight heteroscedasticity (CV<sub>wT</sub> = 70%, CV<sub>wR</sub> = 80%), CV<sub>bT</sub> = CV<sub>bR</sub> = 150%, GMR = 0.85. 222 subjects.<br />
Balanced (222 subjects in both sequences) and complete. No outliers.<br />
The extreme sample size results from high variability, an assumed true GMR 0.85, and target power 90%.<br />
A data frame with 888 observations on the following 5 variables:
</p>

<dl>
<dt>rds08</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
          <code>subject</code> </td><td style="text-align: left;"> a factor with 222 levels: 1, 2, ..., 222</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>period</code> </td><td style="text-align: left;"> a factor with 4 levels: 1, 2, 3, 4</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>sequence</code> </td><td style="text-align: left;"> a factor with 2 levels: TRTR, RTRT</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses acceptable for reference-scaling (generally C<sub>max</sub>)
        </td>
</tr>

</table>

</dd>
</dl>

</li>
<li><p> Reference dataset 09<br />
Based on <code>rds08</code>. Wide numeric range (data of last 37 subjects multiplied by 1,000,000). 222 subjects.<br />
Balanced (222 subjects in both sequences) and complete. No outliers.<br />
A data frame with 888 observations on the following 5 variables:
</p>

<dl>
<dt>rds09</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
          <code>subject</code> </td><td style="text-align: left;"> a factor with 222 levels: 1, 2, ..., 222</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>period</code> </td><td style="text-align: left;"> a factor with 4 levels: 1, 2, 3, 4</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>sequence</code> </td><td style="text-align: left;"> a factor with 2 levels: TRTR, RTRT</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses acceptable for reference-scaling (generally C<sub>max</sub>)
        </td>
</tr>

</table>

</dd>
</dl>

</li>
<li><p> Reference dataset 12<br />
Simulated with extreme intra- and intersubject variability, GMR = 1.6487. 77 subjects.<br />
Unbalanced (39 subjects in sequence TRTR and 38 in RTRT) and incomplete (seven missings in sequence TRTR and three in sequence RTRT). Missings / period: 0/1, 1/2, 7/3, 2/4. No outliers.<br />
A data frame with 298 observations on the following 6 variables:
</p>

<dl>
<dt>rds12</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
          <code>subject</code> </td><td style="text-align: left;"> a factor with 77 levels: 1, 2, ..., 78</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>period</code> </td><td style="text-align: left;"> a factor with 4 levels: 1, 2, 3, 4</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>sequence</code> </td><td style="text-align: left;"> a factor with 2 levels: TRTR, RTRT</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses acceptable for reference-scaling (generally C<sub>max</sub>)
        </td>
</tr>

</table>

</dd>
</dl>

</li>
<li><p> Reference dataset 13<br />
Based on <code>rds08</code>. Highly incomplete (approx. 50% of period 4 data deleted). 222 subjects.<br />
Balanced (111 subjects in both sequences) and incomplete (56 missings in both sequences). Missings / period: 0/0, 0/0, 0/0, 112/4. No outliers.<br />
A data frame with 776 observations on the following 5 variables:
</p>

<dl>
<dt>rds13</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
          <code>subject</code> </td><td style="text-align: left;"> a factor with 222 levels: 1, 2, ..., 222</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>period</code> </td><td style="text-align: left;"> a factor with 4 levels: 1, 2, 3, 4</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>sequence</code> </td><td style="text-align: left;"> a factor with 2 levels: TRTR, RTRT</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses acceptable for reference-scaling (generally C<sub>max</sub>)
        </td>
</tr>

</table>

</dd>
</dl>

</li>
<li><p> Reference dataset 14<br />
Simulated with high variability, GMR = 1. Dropouts as a hazard function growing with period. 77 subjects.<br />
Unbalanced (39 subjects in sequence TRTR and 38 in RTRT) and incomplete (18 missings in sequence TRTR and 17 in sequence RTRT). Missings / period: 0/1, 4/2, 12/3, 19/4. No outliers.<br />
A data frame with 273 observations on the following 6 variables:
</p>

<dl>
<dt>rds14</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
          <code>subject</code> </td><td style="text-align: left;"> a factor with 77 levels: 1, 2, ..., 78</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>period</code> </td><td style="text-align: left;"> a factor with 4 levels: 1, 2, 3, 4</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>sequence</code> </td><td style="text-align: left;"> a factor with 2 levels: TRTR, RTRT</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses acceptable for reference-scaling (generally C<sub>max</sub>)
        </td>
</tr>

</table>

</dd>
</dl>

</li>
<li><p> Reference dataset 15<br />
Based on <code>ref08</code>. Highly incomplete (approx. 50% of period 4 data coded as missing <code>'NA'</code>). 222 subjects.<br />
Balanced (111 subjects in both sequences) and incomplete (56 missings in both sequences). Missings / period: 0/1, 0/2, 0/3, 112/4. No outliers.<br />
A data frame with 888 observations (112 <code>NA</code>) on the following 5 variables
</p>

<dl>
<dt>rds15</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
          <code>subject</code> </td><td style="text-align: left;"> a factor with 222 levels: 1, 2, ..., 222</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>period</code> </td><td style="text-align: left;"> a factor with 4 levels: 1, 2, 3, 4</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>sequence</code> </td><td style="text-align: left;"> a factor with 2 levels: TRTR, RTRT</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses acceptable for reference-scaling (generally C<sub>max</sub>)
        </td>
</tr>

</table>

</dd>
</dl>

</li>
<li><p> Reference dataset 18<br />
Data set based on <code>rds14</code>. Removed T data of subjects 63–78. 77 subjects.<br />
Unbalanced (39 subjects in sequence TRTR and 38 in RTRT) and incomplete (32 missings in sequence TRTR and 31 in sequence RTRT). Missings / period: 8/1, 12/2, 18/3, 25/4. No outliers.<br />
A data frame with 245 observations on the following 6 variables:
</p>

<dl>
<dt>rds18</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
          <code>subject</code> </td><td style="text-align: left;"> a factor with 77 levels: 1, 2, ..., 78</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>period</code> </td><td style="text-align: left;"> a factor with 4 levels: 1, 2, 3, 4</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>sequence</code> </td><td style="text-align: left;"> a factor with 2 levels: TRTR, RTRT</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses acceptable for reference-scaling (generally C<sub>max</sub>)
        </td>
</tr>

</table>

</dd>
</dl>

</li>
<li><p> Reference dataset 19<br />
Data set based on <code>rds18</code>. Removed data of subjects 63–78. 61 subjects.<br />
Unbalanced (31 subjects in sequence TRTR and 30 in RTRT) and incomplete (14 missings in both sequences). Missings / period: 0/1, 4/2, 9/3, 15/4. Two outliers (subjects 18 and 51 in sequence RTRT).<br />
A data frame with 216 observations on the following 6 variables:
</p>

<dl>
<dt>rds19</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
          <code>subject</code> </td><td style="text-align: left;"> a factor with 61 levels: 1, 2, ..., 62</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>period</code> </td><td style="text-align: left;"> a factor with 4 levels: 1, 2, 3, 4</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>sequence</code> </td><td style="text-align: left;"> a factor with 2 levels: TRTR, RTRT</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses acceptable for reference-scaling (generally C<sub>max</sub>)
        </td>
</tr>

</table>

</dd>
</dl>

</li>
<li><p> Reference dataset 20<br />
Data set based on <code>rds19</code>. Extreme outlier of R (subject 1) introduced: original value ×100). 61 subjects.<br />
Unbalanced (31 subjects in sequence TRTR and 30 in RTRT) and incomplete (14 missings in both sequences). Missings / period: 0/1, 4/2, 9/3, 15/4. Two outliers (subjects 1 and 51 in sequence RTRT).<br />
A data frame with 216 observations on the following 6 variables:
</p>

<dl>
<dt>rds20</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
          <code>subject</code> </td><td style="text-align: left;"> a factor with 61 levels: 1, 2, ..., 62</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>period</code> </td><td style="text-align: left;"> a factor with 4 levels: 1, 2, 3, 4</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>sequence</code> </td><td style="text-align: left;"> a factor with 2 levels: TRTR, RTRT</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses acceptable for reference-scaling (generally C<sub>max</sub>)
        </td>
</tr>

</table>

</dd>
</dl>

</li>
<li><p> Reference dataset 21<br />
Based on <code>ds01</code>. 77 subjects. One extreme result of subjects 45 &amp; 52 set to NA.<br />
Unbalanced (39 subjects in sequence TRTR and 38 in RTRT) and incomplete (seven missings in sequence TRTR and five in sequence RTRT). Missings / period: 1/1, 1/2, 8/3, 2/4. No outliers.<br />
A data frame with 298 observations (2 NA) on the following 6 variables:
</p>

<dl>
<dt>rds21</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
          <code>subject</code> </td><td style="text-align: left;"> a factor with 61 levels: 1, 2, ..., 62</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>period</code> </td><td style="text-align: left;"> a factor with 4 levels: 1, 2, 3, 4</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>sequence</code> </td><td style="text-align: left;"> a factor with 2 levels: TRTR, RTRT</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses acceptable for reference-scaling (generally C<sub>max</sub>)
        </td>
</tr>

</table>

</dd>
</dl>

</li>
<li><p> Reference dataset 25<br />
Simulated with heteroscedasticity (CV<sub>wT</sub> = 50%, CV<sub>wR</sub> = 80%), CV<sub>bT</sub> = CV<sub>bR</sub> = 130%, GMR = 0.85. 70 subjects.<br />
Balanced (70 subjects in both sequences) and complete. No outliers.<br />
A data frame with 280 observations on the following 5 variables:
</p>

<dl>
<dt>rds25</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
          <code>subject</code> </td><td style="text-align: left;"> a factor with 70 levels: 1, 2, ..., 70</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>period</code> </td><td style="text-align: left;"> a factor with 4 levels: 1, 2, 3, 4</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>sequence</code> </td><td style="text-align: left;"> a factor with 2 levels: TRTR, RTRT</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses acceptable for reference-scaling (generally C<sub>max</sub>)
        </td>
</tr>

</table>

</dd>
</dl>

</li>
<li><p> Reference dataset 26<br />
54 subjects.<br />
Balanced (27 subjects in both sequences) and incomplete (two missings in both sequences). Missings / period: 0/1, 0/2, 2/3, 2/4. One outlier (subject 49) in sequence RTRT.<br />
A data frame with 216 observations on the following 5 variables:
</p>

<dl>
<dt>rds26</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
          <code>subject</code> </td><td style="text-align: left;"> a factor with 54 levels: 1, 2, ..., 57</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>period</code> </td><td style="text-align: left;"> a factor with 4 levels: 1, 2, 3, 4</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>sequence</code> </td><td style="text-align: left;"> a factor with 2 levels: TRTR, RTRT</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses acceptable for reference-scaling (here C<sub>max</sub>)
        </td>
</tr>

</table>

</dd>
</dl>
<p>In the source evaluated by <abbr><span class="acronym">SAS</span></abbr> for <abbr><span class="acronym">ABEL</span></abbr>. Reported results (Method A):
</p>
<dl>
<dt>SAS Proc GLM</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
          <code>CVwR</code> </td><td style="text-align: left;"> 60.25%</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>PE</code> </td><td style="text-align: left;"> 151.3%</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>90% CI</code> </td><td style="text-align: left;"> 133.5% – 171.4%
        </td>
</tr>

</table>

</dd>
</dl>

</li>
<li><p> Reference dataset 29<br />
Simulated with heteroscedasticity (CV<sub>wT</sub> = 14%, CV<sub>wR</sub> = 28%, CV<sub>bT</sub> = 28%, CV<sub>bR</sub> = 56%), GMR = 0.90. 12 subjects.<br />
Imbalanced (five subjects in sequence TRTR and seven in sequence RTRT) and incomplete (three missings in sequence TRTR and four in sequence RTRT). Missings / period: 0/1, 1/2, 2/3, 4/4. One outlier (subject 11) in sequence RTRT.<br />
A data frame with 41 observations on the following 5 variables:
</p>

<dl>
<dt>rds29</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
          <code>subject</code> </td><td style="text-align: left;"> a factor with 12 levels: 1, 2, ..., 20</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>period</code> </td><td style="text-align: left;"> a factor with 4 levels: 1, 2, 3, 4</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>sequence</code> </td><td style="text-align: left;"> a factor with 2 levels: TRTR, RTRT</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses acceptable for reference-scaling (generally C<sub>max</sub>)
        </td>
</tr>

</table>

</dd>
</dl>

</li></ul>



<h3>Details</h3>


<table>
<tr>
 <td style="text-align: center;">
    Dataset </td><td style="text-align: right;"> N </td><td style="text-align: center;"> CV<sub>wR</sub> (%) </td><td style="text-align: left;"> Evaluation</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds01</code> </td><td style="text-align: right;"> 77 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds06</code> </td><td style="text-align: right;"> 77 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds08</code> </td><td style="text-align: right;"> 222 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds09</code> </td><td style="text-align: right;"> 222 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds12</code> </td><td style="text-align: right;"> 77 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds13</code> </td><td style="text-align: right;"> 222 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds14</code> </td><td style="text-align: right;"> 77 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds15</code> </td><td style="text-align: right;"> 222 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds18</code> </td><td style="text-align: right;"> 77 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds19</code> </td><td style="text-align: right;"> 61 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds20</code> </td><td style="text-align: right;"> 61 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds21</code> </td><td style="text-align: right;"> 77 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds25</code> </td><td style="text-align: right;"> 70 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds26</code> </td><td style="text-align: right;"> 54 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code></td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds29</code> </td><td style="text-align: right;"> 12 </td><td style="text-align: center;"> &lt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code>, <code>ABE()</code>
  </td>
</tr>

</table>



<h3>Note</h3>

<p>In software sequences and treatments are ranked in lexical order. Hence, executing <code>str()</code> or <code>summary()</code> will show <code>sequence</code> as <code>"RTRT", "TRTR"</code> and <code>treatment</code> as <code>"R", "T"</code>. In <abbr><span class="acronym">BE</span></abbr> &ndash; by convention &ndash; sequences are ordered with <code>T</code> first. The package follows this convention.
</p>


<h3>Author(s)</h3>

<p>Helmut Schütz (R-code for simulations by Detlew Labes), Michael Tomashevskiy (simulations in Phoenix NLME)
</p>


<h3>Source</h3>


<table>
<tr>
 <td style="text-align: center;">
    Dataset </td><td style="text-align: left;"> Origin </td><td style="text-align: left;"> Description</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds01</code> </td><td style="text-align: left;"> EMA </td><td style="text-align: left;"> Annex II.</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds06</code> </td><td style="text-align: left;"> <code>rds01</code> edited </td><td style="text-align: left;"> T and R switched.</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds08</code> </td><td style="text-align: left;"> R </td><td style="text-align: left;"> Large simulated data set with slight heteroscedasticity.</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds09</code> </td><td style="text-align: left;"> <code>rds08</code> </td><td style="text-align: left;"> Wide numeric range (data of last 37 subjects multiplied by 1,000,000).</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds12</code> </td><td style="text-align: left;"> Phoenix NLME </td><td style="text-align: left;"> Simulated with extreme intra- and intersubject variability.</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds13</code> </td><td style="text-align: left;"> <code>rds08</code> edited </td><td style="text-align: left;"> Highly incomplete (approx. 50% of period 4 data deleted).</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds14</code> </td><td style="text-align: left;"> Phoenix NLME </td><td style="text-align: left;"> Simulated with high intra-/intersubject variability and</td>
</tr>
<tr>
 <td style="text-align: center;">
     </td><td style="text-align: left;"> </td><td style="text-align: left;">  number of dropouts increasing with period.</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds15</code> </td><td style="text-align: left;"> <code>rds08</code> edited </td><td style="text-align: left;"> Highly incomplete (approx. 50% of period 4 data coded as missing <code>'NA'</code>).</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds18</code> </td><td style="text-align: left;"> <code>rds14</code> edited </td><td style="text-align: left;"> Removed T data of subjects 63–78.</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds19</code> </td><td style="text-align: left;"> <code>rds18</code> edited </td><td style="text-align: left;"> Removed data of subjects 63–78.</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds20</code> </td><td style="text-align: left;"> <code>rds19</code> edited </td><td style="text-align: left;"> Outlier of R (subject 1) introduced: original value ×100.</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds21</code> </td><td style="text-align: left;"> <code>rds01</code> edited </td><td style="text-align: left;"> One extreme result of subjects 45 &amp; 52 set to NA.</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds25</code> </td><td style="text-align: left;"> R </td><td style="text-align: left;"> Simulated with heteroscedasticity.</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds26</code> </td><td style="text-align: left;"> Patterson &amp; Jones </td><td style="text-align: left;"> C<sub>max</sub> data given in Tables 4.40 and 4.31.</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds29</code> </td><td style="text-align: left;"> R </td><td style="text-align: left;"> Simulated with heteroscedasticity; imbalanced and incomplete.
  </td>
</tr>

</table>



<h3>References</h3>

<p>European Medicines Agency. London, 21 September 2016. <a href="https://www.ema.europa.eu/en/documents/other/31-annex-i-statistical-analysis-methods-compatible-ema-bioequivalence-guideline_en.pdf"><em>Annex I</em></a>, <a href="https://www.ema.europa.eu/en/documents/other/31-annex-ii-statistical-analysis-bioequivalence-study-example-data-set_en.pdf"><em>Annex II</em></a>.
</p>
<p>Patterson SD, Jones B. <em>Bioequivalence and Statistics in Clinical Pharmacology.</em> Boca Raton: CRC Press; 2<sup>nd</sup> edition 2016. p105&ndash;6.
</p>


<h3>Examples</h3>

<pre><code class='language-R'>str(rds01)
summary(rds01[2:6])
</code></pre>

<hr>
<h2 id='TRTR.RTRT.TRRT.RTTR'>
Reference Dataset for TRTR|RTRT|TRRT|RTTR Designs
</h2><span id='topic+TRTR.RTRT.TRRT.RTTR'></span><span id='topic+rds23'></span>

<h3>Description</h3>

<p>Dataset from the public domain to be evaluated by <code>method.A()</code> and/or <code>method.B()</code>.
</p>


<h3>Format</h3>


<ul>
<li><p> Reference Dataset 23<br />
22 subjects.<br />
Unbalanced (four subjects in sequence RTRT and six in each of the other three) and complete. Two outliers (subjects 8 and 17) in sequence TRTR.<br />
A data frame with 88 observations on the following 5 variables:
</p>

<dl>
<dt>rds23</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
          <code>subject</code> </td><td style="text-align: left;"> a factor with 22 levels: 1, 2, ..., 27</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>period</code> </td><td style="text-align: left;"> a factor with 4 levels: 1, 2, 3, 4</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>sequence</code> </td><td style="text-align: left;"> a factor with 4 levels: TRTR, RTRT, TRRT, RTTR</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses acceptable for reference-scaling (here C<sub>max</sub>)
          </td>
</tr>

</table>

</dd>
</dl>

</li></ul>



<h3>Details</h3>


<table>
<tr>
 <td style="text-align: center;">
    Dataset </td><td style="text-align: right;"> N </td><td style="text-align: center;"> CV<sub>wR</sub> (%) </td><td style="text-align: left;"> Evaluation</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds23</code> </td><td style="text-align: right;"> 22 </td><td style="text-align: center;"> &gt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code>
  </td>
</tr>

</table>



<h3>Note</h3>

<p>In software sequences and treatments are ranked in lexical order. Hence, executing <code>str()</code> or <code>summary()</code> will show <code>sequence</code> as <code>"RTRT", "RTTR", "TRRT", "TRTR"</code> and <code>treatment</code> as <code>"R", "T"</code>. In <abbr><span class="acronym">BE</span></abbr> &ndash; by convention &ndash; sequences are ordered with <code>T</code> first. The package follows this convention.
</p>


<h3>Source</h3>


<table>
<tr>
 <td style="text-align: center;">
  Data&nbsp;set </td><td style="text-align: left;"> Origin </td><td style="text-align: left;"> Description</td>
</tr>
<tr>
 <td style="text-align: center;">
  <code>rds23</code> </td><td style="text-align: left;"> FDA, CDER </td><td style="text-align: left;"> C<sub>max</sub> data of Drug 7.
  </td>
</tr>

</table>



<h3>References</h3>

<p><abbr><span class="acronym">U.S.</span></abbr> Food and Drug Administration, Center for Drug Evaluation and Research. <em>Bioequivalence Studies.</em> Rockville, 1997. <a href="https://web.archive.org/web/20170723175533/https://www.fda.gov/downloads/Drugs/ScienceResearch/UCM301481.zip">bioequivalence study files</a> (archived 2017-07-23)
</p>


<h3>Examples</h3>

<pre><code class='language-R'>str(rds23)
row &lt;- c(25:28, 5:8, 9:12, 1:4)
rds23[row, ]
summary(rds23[2:5])
</code></pre>

<hr>
<h2 id='TTRR.RRTT'>
Reference Datasets for TTRR|RRTT Designs
</h2><span id='topic+TTRR.RRTT'></span><span id='topic+rds28'></span>

<h3>Description</h3>

<p>Dataset obtained by simulations to be evaluated by <code>method.A()</code> and/or <code>method.B()</code>.
</p>


<h3>Format</h3>


<ul>
<li><p> Reference Dataset 28<br />
64 subjects. Balanced (64 subjects in both sequences) and complete. No outliers.<br />
A data frame with 256 observations on the following 5 variables:
</p>

<dl>
<dt>rds28</dt><dd>

<table>
<tr>
 <td style="text-align: left;">
          <code>subject</code> </td><td style="text-align: left;"> a factor with 64 levels: 1, 2, ..., 64</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>period</code> </td><td style="text-align: left;"> a factor with 4 levels: 1, 2, 3, 4</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>sequence</code> </td><td style="text-align: left;"> a factor with 2 levels: TTRR, RRTT</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>treatment</code> </td><td style="text-align: left;"> a factor with 2 levels: T, R</td>
</tr>
<tr>
 <td style="text-align: left;">
          <code>PK</code> </td><td style="text-align: left;"> a numeric vector of pharmacokinetic responses acceptable for reference-scaling (generally C<sub>max</sub>)
        </td>
</tr>

</table>

</dd>
</dl>

</li></ul>



<h3>Details</h3>


<table>
<tr>
 <td style="text-align: center;">
    Dataset </td><td style="text-align: right;"> N </td><td style="text-align: center;"> CV<sub>wR</sub> (%) </td><td style="text-align: left;"> Evaluation</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds28</code> </td><td style="text-align: right;"> 64 </td><td style="text-align: center;"> &lt;30 </td><td style="text-align: left;"> <code>method.A()</code>, <code>method.B()</code>
  </td>
</tr>

</table>



<h3>Note</h3>

<p>In software sequences and treatments are ranked in lexical order. Hence, executing <code>str()</code> or <code>summary()</code> will show <code>sequence</code> as <code>"RRTT", "TTRR"</code> and <code>treatment</code> as <code>"R", "T"</code>. In <abbr><span class="acronym">BE</span></abbr> &ndash; by convention &ndash; sequences are ordered with <code>T</code> first. The package follows this convention.
</p>


<h3>Author(s)</h3>

<p>Helmut Schütz (R-code for simulations by Detlew Labes)
</p>


<h3>Source</h3>


<table>
<tr>
 <td style="text-align: center;">
    Dataset </td><td style="text-align: left;"> Origin </td><td style="text-align: left;"> Description</td>
</tr>
<tr>
 <td style="text-align: center;">
    <code>rds28</code> </td><td style="text-align: left;"> R </td><td style="text-align: left;"> Simulated with CV<sub>wT</sub> = CV<sub>wR</sub> = 35%, CV<sub>bT</sub> = CV<sub>bR</sub> = 75%, GMR 0.90.
  </td>
</tr>

</table>



<h3>Examples</h3>

<pre><code class='language-R'>str(rds28)
summary(rds28[1:5])
</code></pre>

</main>

</div>
<script src="https://cdnjs.cloudflare.com/ajax/libs/prism/1.29.0/prism.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/prism/1.29.0/components/prism-r.min.js"></script>
</body></html>
